| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
MDxHealth SA$0.43
-0.01 (-3.21%)
Market Cap
41.09 M
EPS
-0.66
P/E Ratio
-
Value Trade
533.52 K
-18.37 %
Week
-65.22 %
1 Month
-77.78 %
3 Month
-75.61 %
6 Month
-93.42 %
5 Year
-93.42 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
1.32 M
52 Week Range
0.68 - 5.33
% held by Insiders
20.25 %
% held by Institutions
39.02 %
Enterprise Value
103.82 M
Total Shares
51.36 M
Short %
0.26 %
Float Shares
40.96 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MDXH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MDxHealth SA (MDXH) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
MDXH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MDXH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MDXH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MDXH Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MDXH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MDXHMdxhealth Reports Q1-2026 Results Conference call with Q&A today at 4:30 PM ET / 22:30
Mdxhealth SA reported its Q1 2026 financial results, revealing a 13% revenue increase to $27.4 million while also announcing the discontinuation of its Resolve UTI business due to reimbursement challenges. CEO Michael K. McGarrity emphasized a renewed focus on the company's core prostate cancer diagnostics and the integration of AI technologies to enhance operational efficiency. The exit from the Resolve business is expected to streamline operations but may incur restructuring costs.
Read more →MDXHMdxhealth Reports Q1-2026 Results
Mdxhealth reported its Q1-2026 financial results, highlighting a 13% revenue increase to $27.4 million. The company has decided to discontinue its Resolve UTI offering due to reimbursement challenges, allowing a renewed focus on its core prostate cancer diagnostics. Despite a slight decrease in net loss, operating expenses rose significantly due to the ExoDx acquisition. The company is optimistic about leveraging AI to enhance its diagnostics offerings.
Read more →MDXHUnofficial English translation - For informational purposes only MDxHealth SA Limited Liability Company ( soci t anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d'Abhooz 31 4040 Herstal, Belgium VAT BE
MDxHealth SA has announced plans for its ordinary and extraordinary general shareholders' meetings scheduled for May 28, 2026. The agenda includes discussions on the financial statements for the year ended December 31, 2025, the re-appointment of directors, and approval of new subscription rights. Significant resolutions include the issuance of new subscription rights and share options. The meetings will be held at the notary public's office in Ghent, Belgium, without an attendance quorum requirement for the ordinary session, while the extraordinary meeting will have specific quorum requirements.
Read more →MDXHMdxhealth to Release First Quarter 2026 Financial Results on May 13
Mdxhealth SA announced it will release its financial results for Q1 2026 on May 13, 2026. The results will be available after market close, followed by a conference call at 4:30 PM ET. The company specializes in precision diagnostics, particularly for prostate cancer and urologic diseases.
Read more →MDXHMdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
Mdxhealth has presented significant data at the EAU 2026 Congress regarding its Genomic Prostate Score (GPS mdx) test, highlighting its ability to predict adverse outcomes in prostate cancer patients across different treatment modalities. The GPS-ProMPT study showed that the test effectively identifies patients with indolent prostate cancer, allowing for potential treatment de-escalation. With a robust sample size and promising six-year freedom-from-failure outcomes, these findings position GPS mdx as a crucial tool in personalized prostate cancer management. The partnership with the University of Oxford is expected to further validate the clinical utility of GPS mdx in future studies.
Read more →MDXHMdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results
MDxHealth reported a 19% revenue growth for Q4 2025, reaching $29.5 million, and a 20% increase for the full year, totaling $107.9 million. The company anticipates continued growth into 2026, with guidance set between $137-140 million. However, net losses rose to $8.9 million in Q4, influenced by higher operating expenses and financial costs.
Read more →MDXHMdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26
Mdxhealth SA, a precision diagnostics company, has announced that it will release its financial results for the fourth quarter and full year of 2025 on February 26, 2026. A conference call is planned for the same day at 4:30pm ET, following the financial results announcement. Participants will have the opportunity to engage in a live Q&A session during the call, adding an interactive element to the update.
Read more →MDXHEXOSOME DIAGNOSTICS, INC. Financial Statements
Exosome Diagnostics, Inc. released its financial statements for the year ending June 30, 2025, highlighting significant operational challenges. The company experienced a net loss of over $86 million, with operating expenses substantially outweighing sales revenue. This raises concerns regarding the company’s financial stability and its ability to continue operations, particularly given the overwhelming losses and liabilities reported in their statements.
Read more →MDXHMDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences IRVINE, CA
MDxHealth reported preliminary revenues of approximately $30.5 million for the fourth quarter and $109 million for the full year 2025, highlighting year-over-year growth of 23% and 21%, respectively. The company issued a 2026 revenue guidance of $137-140 million, projecting an increase of 26-28%. Additionally, MDxHealth amended its earnout terms with Exact Sciences, deferring payments over several years and issuing warrants. The CEO expressed confidence in achieving sustainable growth driven by their sales strategy and expanded offerings.
Read more →MDXHMdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer
Mdxhealth has initiated a significant collaboration with the University of Oxford to validate its Genomic Prostate Score (GPS) test in the ProtecT trial, the largest randomized study of treatment effectiveness in localized prostate cancer. This trial seeks to provide critical evidence supporting the clinical utility of GPS for predicting disease progression and treatment outcomes. The collaboration is expected to reshape clinical practice guidelines and enhance the personalization of care for prostate cancer patients worldwide.
Read more →MDXHMdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025
MDxHealth reported a strong financial performance for Q3 2025, with an 18% increase in revenue to $27.4 million and positive adjusted EBITDA of $1.0 million. The company highlighted the acquisition of Exosome Diagnostics, which is expected to enhance its product offerings. Despite a net loss of $8.0 million, MDxHealth remains optimistic about achieving its full-year revenue guidance of $108 million to $110 million.
Read more →MDXHMdxhealth to Release Third Quarter 2025 Financial Results on November 12
MDxHealth SA will announce its third quarter financial results for 2025 on November 12, after market close. A conference call with a live Q&A session will follow at 4:30 PM ET. The company emphasizes its role in precision diagnostics, providing vital molecular information for patient care.
Read more →MDXHMdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne
Mdxhealth has finalized its acquisition of Exosome Diagnostics from Bio-Techne, which includes the ExoDx Prostate test. The total deal is valued at $15 million, with a combination of cash and stock payments. This acquisition is expected to strengthen Mdxhealth's position in precision diagnostics, particularly in urologic cancers.
Read more →MDXHINTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT 2 II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA 5 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER C
MDxHealth has reported its interim financial results for the six months ending June 30, 2025, showcasing significant revenue growth of 21% year-on-year. Despite achieving an increase in gross profit and a notable reduction in operating loss, the company continues to face challenges such as a substantial accumulated deficit and ongoing net losses. Management's ability to maintain its operations hinges on accessing future financing and achieving positive cash flows. The report emphasizes the uncertainty surrounding the company's long-term viability amid these financial challenges.
Read more →MDXHMdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
MDxHealth reported a 20% increase in Q2 2025 revenues, reaching $26.6 million, and achieved positive adjusted EBITDA of $1.4 million. The company announced an agreement to acquire the ExoDx business from Bio-Techne for $15 million, which is expected to enhance its diagnostic capabilities and revenue growth. MDxHealth reaffirmed its 2025 revenue guidance of $108-110 million.
Read more →MDXHMdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change
MDxHealth has appointed Michael Holder as the Chair of the Audit Committee, succeeding Regine Slagmulder. Holder brings over 30 years of experience in various executive roles. Additionally, CFO Ron Kalfus will resign on July 30, 2025, with Scott McMahan taking over interim CFO duties. The company expresses gratitude for Kalfus's contributions during his tenure.
Read more →MDXHMDxHealth Reports Q1-2025 Results
MDxHealth reported strong financial results for Q1 2025, with revenues increasing by 22% year-over-year to $24.3 million. The company achieved a 71% improvement in adjusted EBITDA, indicating better operational efficiency. Despite a rising net loss of $9.2 million, MDxHealth remains optimistic, reaffirming its revenue guidance for the year.
Read more →MDXHMDxHealth SA and Subsidiaries UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS Three Months Ended March 31, In thousands of $ (except per share amounts) 2025 2024 Revenues $ 24,292 $ 19,834 Cost of sales (exc
MDxHealth SA reported their condensed consolidated financial results for the three months ending March 31, 2025. The company experienced a revenue increase to $24.29 million, up from $19.83 million in the same period the previous year. However, operating loss and total losses for the period both grew, with losses increasing to $9.21 million. Additionally, the company's total liabilities rose to approximately $168.87 million, reflecting increased financial obligations.
Read more →MDXHReport of the board of directors This report of the board of directors has been prepared in accordance with the Articles 3:5, 3:6, 1 and 3:32, 1 of the Belgian Companies and Associations Code of 23 March 2019 (as amended
MDxHealth SA reported a notable recovery in its financial performance for the year ending December 31, 2024, with total revenues increasing by 28% to EUR 3,979,160 compared to EUR 3,233,610 in 2023. The company's net profit stood at EUR 7,031,447, significantly reversing the previous year's losses. Despite this positive outlook, MDxHealth faces challenges with a cumulative loss of EUR 196,464,303 and continues to depend on future funding and revenue generation to ensure operational stability. The financial results will be presented to shareholders for approval at the upcoming general meeting scheduled for May 28, 2025.
Read more →MDXHMdxhealth to Release First Quarter 2025 Financial Results on May 14
MDxHealth SA has announced it will release its financial results for the first quarter of 2025 on May 14, following market close. The announcement includes details about a subsequent conference call featuring CEO Michael K. McGarrity and CFO Ron Kalfus. Interested parties can participate via a dial-in or through a webcast, with access to a replay afterward. This event signifies the company's commitment to transparency and investor relations.
Read more →MDXHMdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results
MDxHealth reported a strong financial performance for Q4 and full-year 2024, with revenues growing by 28% to $24.7 million in Q4 and $90 million for the year. The company achieved a 68% improvement in adjusted EBITDA, signaling progress towards profitability. Despite a net loss of $6.8 million, MDxHealth maintains a positive outlook for 2025, projecting revenues of $108-110 million.
Read more →MDXHMdxhealth to Present Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on February 26
MDxHealth SA will announce its fourth quarter and full year 2024 financial results on February 26, 2025. The company will host a conference call with a live Q&A session at 4:30 PM ET. A replay of the webcast will be available on the company's website after the live event.
Read more →MDXHMDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance
MDxHealth reported preliminary revenues for Q4 and full year 2024, with revenues of approximately $24.7 million and $90 million, respectively, marking a 28% year-over-year growth. The company also provided 2025 revenue guidance of $108-110 million, reflecting a projected growth of 20-22%. CEO Michael K. McGarrity expressed confidence in the company's growth strategy and market position.
Read more →MDXHMDxHealth to Participate in Piper Sandler Healthcare Conference
MDxHealth SA has announced its participation in the Piper Sandler 36th Annual Healthcare Conference, scheduled for December 3-5, 2024, in New York City. CEO Michael K. McGarrity will take part in a fireside chat on December 4, from 3:00 to 3:25 pm ET. A live webcast of this discussion will be available through MDxHealth's investor page. This event is expected to increase the company's visibility in the precision diagnostics field.
Read more →MDXHMDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024
MDxHealth SA reported significant financial improvements for the third quarter and nine-month period ended September 30, 2024, with a 21% year-over-year revenue growth. The company has raised its 2024 revenue guidance to between $87 million and $89 million, reflecting a robust demand for its diagnostic tests. Despite these positive indicators, MDxHealth faced an increase in operating and net losses due to higher expenses and a variation in product mix, leading to a slight decline in gross margins. Overall, the outlook remains optimistic with expectations for continued growth in the coming years.
Read more →MDXHCONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS Three Months Ended September 30, Nine Months Ended September 30, Thousands of $ (except per share data) 2024 2023 2024 2023 Revenues 23,317 19,350 65,310 50,79
MDXH reported its financial results for the third quarter and nine months ended September 30, 2024. The company saw an increase in revenues to $23,317 for Q3, up from $19,350 in the prior year. Gross profit also improved, but the company continued to experience an operating loss, which grew to $6,092 compared to $4,561 in Q3 of 2023. The accumulated deficit increased further, indicating ongoing financial challenges despite some revenue growth.
Read more →MDXHMDxHealth to Present Third Quarter 2024 Financial Results and Corporate Update on November 6
MDxHealth SA has announced it will release its third quarter financial results for 2024 on November 6. Following the announcement, the company will host a conference call at 4:30pm ET with live Q&A, aimed at providing an interactive platform for stakeholders. The details of the call and webcast are shared, and a replay will be available on the company's website after the event.
Read more →MDXHMDxHealth Announces Pricing of Offering of Ordinary Shares
MDxHealth has announced the pricing of a public offering of 20 million ordinary shares at $2.00 per share, aiming to generate total gross proceeds of $40 million. A strategic partner will acquire 1.5 million shares directly from the company, while underwriters have the option to purchase additional shares. The funds raised will be used for general corporate purposes, including product development and commercial activities, with the offering expected to close on September 27, 2024. However, the completion of the offering is subject to market conditions and there are inherent risks associated with the forward-looking statements made by the company.
Read more →MDXHMDxHealth Announces Launch of Offering of Ordinary Shares
MDxHealth SA announced the launch of a proposed public offering of $40 million of ordinary shares. The offering is managed by TD Cowen and William Blair, who will also receive an option to purchase additional shares. The completion and terms of the offering are uncertain and depend on market conditions. The company will distribute a preliminary prospectus supplement through its registration statement filed with the SEC.
Read more →MDXHSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this " Agreement ") is dated as of
MDxHealth SA announced a successful capital increase of $40 million through the issuance of 20 million new Ordinary Shares priced at $2.00 each. The offering was approved by the company's board and aimed at both retail and institutional investors in the United States. Genomic Health, Inc. made a significant subscription order for 1.5 million shares as part of this agreement, highlighting ongoing investor interest and engagement.
Read more →MDXHMDxHealth Reports Q2 and Half Year 2024 Results
MDxHealth reported significant financial growth in its Q2 and half-year results for 2024, with revenues rising by 32% year-over-year to $22.2 million. The company also experienced a 34% increase in half-year revenues, totaling $42 million. Although net losses increased by 8% due to refinancing costs, the CEO expressed confidence in future growth driven by strong demand for its precision diagnostic tests. The firm anticipates sustainable revenue growth with plans for broader market opportunities.
Read more →MDXHINTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT 1 II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA 3 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER C
MDxHealth reported its interim financial results for the six months ending June 30, 2024, indicating a revenue increase of 34% year-over-year to $42.0 million. The company demonstrated improved gross profit margins, though it still faces net losses totaling $20.0 million. Management acknowledges significant risks, including an accumulated deficit of $351.5 million, casting doubt on its ability to continue operations. Nevertheless, the company believes it can sustain operations for the next twelve months due to available cash and access to additional financing.
Read more →MDXHMDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21
MDxHealth SA is set to announce its financial results for the second quarter and first half of 2024 on August 21, 2024, after market close. The company will also host a conference call at 4:30 PM ET, featuring CEO Michael K. McGarrity and CFO Ron Kalfus. Investors can participate in a live Q&A session during the call. This financial update may provide insights into the company's performance during the first half of the year.
Read more →MDXHMdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors IRVINE, CA, and HERSTAL, BELGIUM
MDxHealth has appointed Dr. Sanford J. Siegel to its Board of Directors, succeeding Lieve Verplancke, M.D. Dr. Siegel brings over 45 years of experience as a urologist and extensive leadership roles in the urology sector. His background as Chairman of the United Urology Group and founder of Chesapeake Urology Associates positions him as a valuable asset to mdxhealth. The appointment is seen as a strategic move in the company's mission to enhance prostate cancer diagnostics and treatment pathways.
Read more →MDXHMDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance
MDxHealth SA has reported preliminary Q2 and half year 2024 revenues of $22.2 million and $42 million, indicating year-over-year growth of 32% and 34%, respectively. The company has raised its full-year revenue guidance to a range of $85-87 million based on strong expected growth. CEO Michael K. McGarrity expressed confidence in meeting an adjusted EBITDA profitability target by the first half of 2025. However, the financial data are subject to adjustments as they have not yet been finalized and are based on preliminary reports.
Read more →MDXHNEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FRO
MDxHealth SA has issued Warrants related to its acquisition of the Oncotype DX Genomic Prostate Score test from Exact Sciences. These securities have not been registered under the US Securities Act, which restricts their sale unless certain conditions are met. Each Warrant allows the holder to acquire one share at an exercise price of USD 5.265, but they will expire on August 22, 2028, unless exercised beforehand. This regulatory status can affect the availability and potential profitability for investors.
Read more →MDXHMdxhealth to Present at Upcoming Investor Conferences
Mdxhealth SA, a precision diagnostics company, has announced its participation in two investor conferences in June 2024. CEO Michael K. McGarrity will present at the William Blair 44th Annual Growth Stock Conference on June 5 and at the Jefferies Global Healthcare Conference on June 6. Live webcasts of the presentations will be accessible on the company's investor page, with replays available for 60 days post-event. This engagement underscores Mdxhealth's strategy to connect with investors and share its advancements in the industry.
Read more →MDXHMDxHealth SA and Subsidiaries UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS Three Months Ended March 31, In thousands of $ (except per share amounts) 2024 2023 Revenues $ 19,834 $ 14,700 Cost of sales (exc
MDxHealth SA reported its unaudited financial results for Q1 2024, showing a revenue increase to $19,834 from $14,700 in Q1 2023. Despite this growth, the company faced a net loss of $8,511, although it was an improvement from the previous year's loss of $11,709. The gross profit also improved, rising to $12,063 compared to $8,715 a year earlier. However, the decrease in cash and total equity raises concerns about the company's financial stability.
Read more →MDXHMDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 million Increasing 2024 revenue guidance to $83-85 million, previously $79-81 million Confer
MDxHealth reported a strong performance in Q1 2024, with revenues rising by 35% to $19.8 million, prompting an increase in revenue guidance for the year. The company secured a $100 million loan from OrbiMed to support its growth strategy and attract institutional investors. Despite an operating loss, the company highlighted improvements in cash burn and optimistic projections for revenue contributions from new testing services. Management expressed confidence in achieving adjusted EBITDA profitability in the first half of 2025.
Read more →MDXHMdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM
MDxHealth SA has introduced a new non-invasive genetic test for hereditary prostate cancer, enhancing its prostate cancer diagnostic offerings. This test, which uses a simple saliva sample, aids in understanding risks, disease progression, and treatment responses. The move aligns with National Comprehensive Cancer Network guidelines and is covered by Medicare and many commercial insurance plans. The CEO believes this addition will contribute positively to the company's revenue growth later this year.
Read more →MDXHMdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42% 2023 gross margin expanded by 10.7 percentage points over prior year Confe
MDxHealth announced a strong financial performance for the fourth quarter and full year 2023, with revenue increasing by 89% to $70.2 million. The company reported significant gross margin expansion and a decrease in operating losses. CEO Michael K. McGarrity emphasized ongoing commitments to operational discipline and growth opportunities. For 2024, MDxHealth maintains a revenue guidance of $79-81 million and expects to achieve adjusted EBITDA profitability in the first half of 2025.
Read more →MDXHMDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
MDxHealth SA has announced that it will present its financial results for the fourth quarter and the full year of 2023 on March 6, 2024. The announcement includes details for a conference call at 4:30 PM ET, which will feature executives from the company. This update suggests the company is moving forward with its operational priorities and maintaining transparency with its investors and stakeholders.
Read more →MDXHMdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM
MDxHealth has announced the resignation of board member Jan Pensaert, effective February 15, 2024. The company clarified that his departure was not due to any disagreements regarding operations or policies. CEO Michael K. McGarrity acknowledged Pensaert's support and contributions during a transformative period for MDxHealth.
Read more →MDXHMdxhealth Announces Resignation of Board Member
MDxHealth SA announced the resignation of board member Jan Pensaert, effective February 15, 2024. The company clarified that his departure was not due to any disagreements regarding its operations, policies, or practices. CEO Michael K. McGarrity expressed gratitude for Pensaert's contributions during a period of transformation for the company. This change in the board may signify ongoing shifts within the company's strategic direction.
Read more →MDXHMDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM
MDxHealth reported preliminary revenues for the fourth quarter and full year 2023, estimating approximately $19.4 million and $70.2 million, respectively. The company also provided 2024 revenue guidance of $79-81 million, signifying continued growth. CEO Michael K. McGarrity expressed confidence in the company's sales strategy and product offerings. However, the reported figures are preliminary and may be subject to material adjustments following auditing.
Read more →MDXHMDxHealth Announces Completion of Transition to Single Listing on Nasdaq
MDxHealth has successfully completed its transition to a single listing on Nasdaq, which means its shares will no longer be traded on Euronext Brussels. The last trading day on Euronext was December 15, 2023, and the shares are now exclusively listed on Nasdaq. All shares retain their validity, including voting rights and rights to future dividends, and can still be repositioned by shareholders at any time after this transition.
Read more →MDXHREGULATED INFORMATION DECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET MDxHealth Announces Completion of Transition to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM
On December 18, 2023, MDxHealth announced the successful completion of its transition to a single listing on the Nasdaq Stock Market. This move follows the company's prior announcements about the delisting of its shares from Euronext Brussels, with the last trading day occurring on December 15, 2023. The transition is expected to provide shareholders with a streamlined trading experience on Nasdaq while maintaining the integrity and rights of their shares. MDxHealth, known for its precision diagnostics in urologic health, aims to enhance its market presence through this singular listing.
Read more →MDXHMDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq
MDxHealth has completed its Mandatory ADS Exchange, consolidating all trading of its securities to Nasdaq after a 1-for-10 reverse stock split. This strategic move is expected to enhance trading efficiency and consolidate shareholder value under a single exchange in the U.S. The company will maintain its listing on both Euronext Brussels and Nasdaq during a transition period until December 15, 2023, after which it will exclusively trade on Nasdaq. Shareholders are encouraged to reposition their shares from Euronext Brussels to Nasdaq, with full rights retained throughout the process.
Read more →MDXHREGULATED INFORMATION NOVEMBER 27, 2023, 1:00 am ET / 7:00 am CET MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq IRVINE, CA, and
MDxHealth has announced the successful completion of its Mandatory ADS Exchange, which allows for the transition of its shares to a single listing on Nasdaq. This involves a reverse stock split and the cessation of ADS trading, as all securities will now be concentrated on Nasdaq. Effective immediately, shareholders can begin the process of repositioning their shares from Euronext Brussels to Nasdaq, with the transition period set to last until December 15, 2023. This strategic move aims to consolidate trading activities in the U.S. market.
Read more →MDXHMDxHealth to Participate in the 35th Annual Piper Sandler Healthcare Conference
MDxHealth SA announced that its CEO, Michael K. McGarrity, will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference. The conference is scheduled for November 28-30, 2023, in New York City. A live webcast of the chat will be available on MDxHealth's website, suggesting a strategy to enhance investor and market engagement during this event.
Read more →MDXHMDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights
MDxHealth SA has successfully completed a share consolidation, transitioning from 272,880,936 shares to 27,288,093 shares through a reverse stock split of 1-for-10. This move aims to enhance share value and improve market perception as trading begins on Euronext Brussels for the new shares. The company announces that subscription rights and securities on Nasdaq will be adjusted accordingly following the consolidation. Additionally, the process for selling new shares from consolidated old shares is expected to be completed by November 23, 2023.
Read more →MDXHREGULATED INFORMATION INSIDE INFORMATION NOVEMBER 13, 2023, 4:00 PM ET / 22:00 CET MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights IRVINE, CA, and
MDxHealth has successfully completed a share consolidation with a 1-for-10 reverse stock split, reducing its outstanding shares from 272.8 million to 27.3 million. The new shares will begin trading on Euronext Brussels on November 14, 2023. The move is part of the company's strategy to transition to a sole listing on Nasdaq, aimed at enhancing shareholder value and market presence. Additionally, stakeholders must adjust their subscription rights accordingly due to the consolidation changes.
Read more →MDXHMDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023
MDxHealth SA reported strong financial results for the third quarter and nine-month period ending September 30, 2023. The company experienced a revenue increase of 73% year-over-year in Q3, driven by gains across its product offerings. However, net loss only decreased by 2% compared to the previous year, influenced by rising financial expenses. The company also announced a transition to a sole listing of shares on NASDAQ following a successful shareholders' meeting.
Read more →MDXHREGULATED INFORMATION 8 NOVEMBER 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended
MDxHealth reported positive financial results for the third quarter and nine-month period ending September 30, 2023, showcasing strong revenue growth and improved gross profit margins. The company's revenue increased 73% year-over-year for Q3 and 110% for the nine-month period. Despite these advancements, MDxHealth continued to incur net losses, although they were less severe compared to the previous year. The company is also undertaking a transition to a sole listing of its shares on NASDAQ and has amended earnout agreements with Exact Sciences, deferring payments but increasing potential future earnout amounts.
Read more →MDXHMDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation
MDxHealth announced that its shareholders approved the transition from a dual listing on Nasdaq and Euronext Brussels to a sole listing on Nasdaq. This approved transition includes a share consolidation through a 1-for-10 reverse stock split. Key dates for implementation include the last trading day on Euronext Brussels on November 13, 2023, and the admission to trading on Nasdaq on November 27, 2023. The move is aimed at enhancing the company's market presence and streamlining its operations.
Read more →MDXHREGULATED INFORMATION INSIDE INFORMATION NOVEMBER 6, 2023, 1:00 AM ET / 7:00 CET MDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and D
MDxHealth announced that its shareholders approved the transition to a sole listing of shares on Nasdaq and the implementation of a 1-for-10 reverse stock split. The decision was made during an extraordinary general meeting on November 3, 2023. The expected timeline includes the first trading day of new shares on Euronext Brussels on November 14, 2023, and the mandatory exchange on November 27, 2023. The company aims to simplify its trading by moving from a dual listing to a single listing in the United States.
Read more →MDXHMDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8
MDxHealth has announced that it will release its financial results for the third quarter of 2023 after market close on November 8, 2023. The company will also host a conference call that includes a live Q&A session, allowing stakeholders to engage directly with executives. This update highlights the company's ongoing commitment to transparency and communication with investors.
Read more →MDXHOctober 20, 2023, 4:00 PM EDT / 22:00 CET
MDxHealth SA announced a successful capital increase, raising its share capital from EUR 163,471,629.58 to EUR 164,302,752.89. This increase was achieved through the issuance of 2,500,000 new shares, bringing the total number of issued shares to 272,880,936. The new shares are part of an acquisition agreement for the Oncotype DX GPS test. MDxHealth focuses on providing diagnostic tests for urologic cancers and related diseases, utilizing advanced molecular technologies.
Read more →MDXHMdxhealth's New Share Capital Amount and New Number of Shares
MDxHealth SA has announced an increase in its share capital from EUR 163,471,629.58 to EUR 164,302,752.89 following a successful capital increase on October 20, 2023. The total number of issued shares has grown by 2,500,000 to reach 272,880,936. This capital raise is linked to the company's acquisition of the Oncotype DX GPS test, a key component of its precision diagnostics strategy. Additionally, subscription rights and terms for the conversion of loans into American Depositary Shares were outlined, demonstrating ongoing financial maneuvers.
Read more →MDXHINSIDE AND REGULATED INFORMATION 9 OCTOBER 2023, 4PM ET / 22:00 CET MDxHealth Reports Preliminary Q3-2023 Revenues IRVINE, CA, and HERSTAL, BELGIUM
MDxHealth company has reported preliminary revenues for Q3 2023, projecting approximately $19.3 million, marking a 73% increase from the prior year. This growth includes significant contributions from their diagnostic products, particularly from Resolve mdx which saw a 101% rise in revenue. The company is maintaining a solid cash position and reduced cash usage by nearly 23% from the previous quarter. However, they face uncertainties regarding future market conditions and regulatory approvals, which could impact their anticipated growth.
Read more →MDXHMDxHealth Reports Preliminary Q3-2023 Revenues
MDxHealth SA reported preliminary revenues of approximately $19.3 million for Q3-2023, reflecting a 73% increase from the same period last year and a 15% increase from the previous quarter. This growth is attributed to various diagnostic products, with Confirm mdx showing a 15% increase in billable tests and Resolve mdx up by an impressive 101%. Additionally, the company's cash position stood at $32.7 million, and it is expected to release full Q3 results on November 8, 2023.
Read more →MDXHFree English translation for information purposes only MDxHealth SA Limited Liability Company ( soci t anonyme ) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d'Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292
MDxHealth SA provided a free English translation of company-related information for informational purposes. The document includes details such as their business location in Herstal, Belgium, and the total number of outstanding shares and voting rights as of October 4, totaling 270,380,936. This overview complies with the Belgian Companies and Associations Code.
Read more →MDXHMDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting
MDxHealth has announced a proposed transition to delist from Euronext Brussels and list exclusively on Nasdaq. The plan includes a 1-for-10 reverse stock split to consolidate shares and a mandatory exchange of American Depositary Shares for regular shares. An extraordinary general shareholders' meeting is scheduled for November 3, 2023, to secure approval for these changes. The CEO believes that this transition will significantly enhance trading efficiency and reduce operating costs.
Read more →MDXHMdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer
MDxHealth has entered a research collaboration with the University of Oxford to investigate the Genomic Prostate Score (GPS) test's correlation with the progression of localized prostate cancer. This effort aims to enhance risk assessment and treatment personalization for patients. The collaboration utilizes patient samples from the Prostate Mechanisms of Progression and Treatment (ProMPT) cohort, which has been operational since 2002. Company executives express optimism about the potential of the GPS test to improve clinical outcomes, although they acknowledge associated risks in their forward-looking statements.
Read more →MDXHMDxHealth Reports Q2 and Half Year 2023 Results
MDxHealth S.A. reported substantial financial growth for Q2 and the first half of 2023, highlighting a 143% increase in quarter revenues to $16.7 million and a gross margin improvement to 59.7%. The company reaffirmed its revenue guidance for the full year at $65-70 million. Despite the positive growth, MDxHealth reported a net loss increase of $4.2 million year-over-year and a significant rise in operating expenses due to expanding its sales force. Recent amendments to the GPS purchase agreement with Exact Sciences have deferred earn-out payments, offering potential financial flexibility.
Read more →MDXHINTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT 2 II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA 4 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER C
MDxHealth SA's interim report for the first half of 2023 shows a significant revenue increase of 142% compared to the previous year, primarily driven by its GPS products. However, the company still reported a net loss of $22.3 million, which is greater than the loss of $18.1 million from the same period last year. Operating expenses have also risen by 54%, raising concerns regarding the company's ongoing profitability and ability to sustain operations in the near term. Despite these challenges, improvements in gross profit and margins signal potential for growth.
Read more →MDXHMDxHealth to Present Q2 and Half Year 2023 Financial Results and Corporate Update on August 23
MDxHealth SA has announced that it will release its financial results for the second quarter and the first half of 2023 on August 23, 2023. The company plans to host a conference call featuring its CEO and CFO to discuss the results, which will be accessible via a webcast. This event underscores MDxHealth's commitment to keeping stakeholders informed about its financial performance and corporate developments.
Read more →MDXHAUGUST 2023, 4PM ET / 22:00 CET Cigna Expands Commercial and Medicare Advantage Coverage to Include Mdxhealth's Select mdx for Prostate Cancer Test Expansion of coverage with Cigna now includes full menu o
MDxHealth SA announced that Cigna will expand its commercial and Medicare Advantage coverage to include the Select mdx for Prostate Cancer test. This decision allows more than 15 million lives to access MDxHealth's full menu of precision diagnostic tests. The Select mdx test offers a non-invasive method to assess the risk of clinically significant prostate cancer. The coverage is expected to take effect in the fourth quarter of this year and aligns with MDxHealth's strategic priorities in improving prostate cancer diagnosis and management.
Read more →MDXHREGULATED INFORMATION 30 June 2023, 10:00 p.m. CEST MDxHealth Announces Results of its Extraordinary General Shareholders' Meeting IRVINE, CA, and HERSTAL, BELGIUM - 30 June 2023 - MDxHealth SA (Nasdaq and
MDxHealth SA has announced the results of its Extraordinary General Shareholders' Meeting held on June 30, 2023. During the meeting, shareholders approved the new '2023 Share Option Plan' and renewed the authorization for the board to increase share capital despite a lack of attendance quorum. All proposed resolutions were passed successfully. MDxHealth continues to focus on providing precision diagnostics for urologic cancers and operates in multiple locations in the U.S. and Europe.
Read more →MDXHMDxHealth Announces Results of its Extraordinary General Shareholders’ Meeting
MDxHealth SA held an extraordinary general shareholders' meeting on June 30, 2023, where key items such as the '2023 Share Option Plan' and share capital increase authorization were discussed. Although there was no attendance quorum, all proposed resolutions were successfully passed. The meeting reflects the company's ongoing efforts to implement strategic measures for growth and employee engagement.
Read more →MDXHMDxHealth Announces its Extraordinary General Shareholders’ Meeting
MDxHealth has announced an extraordinary general shareholders' meeting scheduled for June 30, 2023, where key agenda items include the launch of a new share option plan and the renewal of authorization for capital increase by the board of directors. Shareholders are encouraged to comply with specific regulations and formalities to participate. The convening notice and related documents are available on the company's website.
Read more →MDXHREGULATED INFORMATION 25 May 2023, 22:30 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders' Meetings IRVINE, CA, and HERSTAL, BELGIUM - 25 May 2023 - MDxHealth SA (Nasdaq
MDxHealth announced the outcomes of its Annual and Extraordinary General Shareholders' Meetings held on May 25, 2023. The AGM was able to pass all proposed resolutions, although it did not meet the necessary quorum. Meanwhile, the EGM will reconvene on June 30, 2023, due to failing to achieve the quorum required for decision-making in the first meeting.
Read more →MDXHMDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings
MDxHealth held its annual general shareholders' meeting where all resolutions related to the financial year ending December 31, 2022, were approved. However, the meeting did not meet the necessary quorum for attendance. Consequently, a new extraordinary general shareholders' meeting is scheduled for June 30, 2023, which will not require an attendance quorum. This indicates ongoing governance challenges within the company.
Read more →MDXHMDxHealth to Present at the 43rd Annual William Blair Growth Stock Conference
MDxHealth announced that CEO Michael McGarrity will present at the 43rd Annual William Blair Growth Stock Conference on June 8, 2023. The presentation will be accessible via a live webcast on the company's website. The conference, which will be held from June 6 to 8, 2023, takes place at the Loews Chicago Hotel in Chicago, IL. This event highlights MDxHealth's engagement with investors and the market.
Read more →MDXHMDxHealth Reports Q1-2023 Results
MDxHealth reported significant growth in its Q1 2023 results, with revenues reaching $14.7 million, a 141% increase year-over-year, driven by strong sales performance and expanded test coverage. Additionally, the company achieved a gross margin of 59.3%, improving its financial health. The announcement of Medicare coverage for the Select mdx test is expected to further enhance revenue prospects, despite an increase in operating and net losses. The CEO emphasized the company's continued commitment to growth through operational discipline and market strategy.
Read more →MDXHREGULATED INFORMATION 15 MAY 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Q1-2023 Results Year-over-year revenues increase by 141% to $14.7 million; excluding GPS, revenues up 39% Gross margin expanded b
MDxHealth announced its Q1-2023 financial results, showcasing a substantial year-over-year revenue increase of 141%, totaling $14.7 million. The company reported a significant improvement in gross profit margins, primarily driven by its product mix and the addition of GPS to its offerings. However, operating expenses rose sharply, contributing to a net loss of $11.7 million, which is a $3.4 million increase from the same period last year. Notably, the Select mdx test has secured Medicare reimbursement, expanding its market reach and potential for growth going forward.
Read more →MDXHMDxHealth to Present First Quarter 2023 Financial Results on May 15
MDxHealth SA has announced it will present its financial results for the first quarter of 2023 on May 15, 2023, after market close. The company will host a conference call and live Q&A session at 4:30 PM ET. This event will feature CEO Michael K. McGarrity and CFO Ron Kalfus, who will discuss the performance and outlook of the company. Investors and interested stakeholders are encouraged to participate in the call to gain insights into MDxHealth's current standing and future plans.
Read more →MDXHREGULATED INFORMATION APRIL 25, 2023, 4:00 pm ET/ 22:00 CET MDxHealth Announces its Ordinary and Extraordinary General Shareholders' Meetings IRVINE, CA, and HERSTAL, BELGIUM
MDxHealth SA has announced its upcoming ordinary and extraordinary general shareholders' meetings scheduled for May 25, 2023. The agenda includes the approval of resolutions related to the 2022 financial year, renewing board mandates, and introducing the '2023 Share Option Plan'. Shareholders are required to comply with specific formalities to participate, which can be found in the convening notice on the company's website. This move is part of MDxHealth's ongoing commitment to advancing its precision diagnostics capabilities.
Read more →MDXHMDxHealth Announces its Ordinary and Extraordinary General Shareholders’ Meetings
MDxHealth SA has announced its ordinary and extraordinary general shareholders' meetings scheduled for May 25, 2023. The agenda will include the approval of resolutions related to financials from the previous year, the renewal of board mandates, and the introduction of a new share option plan. Additionally, the authorization to increase share capital will be discussed, showcasing the company's strategic plans for future growth.
Read more →MDXHmost recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission.
MDxHealth has announced that its Select mdx for Prostate Cancer test has successfully completed a technical assessment by the Molecular Diagnostics Services Program. This accomplishment allows for reimbursement for Medicare patients meeting specific criteria under the Local Coverage Determination for Molecular Biomarkers. The CEO highlighted the positive impact of this coverage, emphasizing the importance of the test in stratifying patients at risk for prostate cancer. Additionally, the test has been included in the NCCN Guidelines, elevating its credibility and potential market adoption.
Read more →MDXHREGULATED INFORMATION APRIL 7, 2023, 4:30 pm ET/ 22:30 CET MDxHealth Shareholder Transparency Declaration IRVINE, CA, and HERSTAL, BELGIUM
MDxHealth has announced a shareholder transparency declaration per Belgian regulations, revealing that Valiance Asset Management Limited's voting rights have dropped below 10% of the company's outstanding shares. The notification disclosed that Valiance holds a total of 20,931,094 shares, equivalent to 7.96% of MDxHealth’s shares. This declaration is part of the company's obligation under the Belgian Transparency Act regarding significant participations in a publicly traded entity.
Read more →MDXHMDxHealth Shareholder Transparency Declaration
MDxHealth SA has disclosed under the Belgian Transparency Act that Valiance Asset Management Limited has reduced its holdings to below 10% of the company's outstanding shares. The notification indicates that Valiance Asset Management Limited now holds approximately 7.96% of MDxHealth's shares, equating to 20,931,094 shares. This change in shareholding is part of the regulatory requirements aimed at ensuring shareholder transparency.
Read more →MDXHMDxHealth Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
MDxHealth SA has officially stated that it has no exposure to Silicon Valley Bank or Silvergate Bank, which are facing significant financial issues. This announcement is aimed at assuring stakeholders of the company's financial health amidst banking sector instability. MDxHealth's confirmation highlights its focus on maintaining operational stability and mitigating risks related to current market challenges.
Read more →MDXHREGULATED INFORMATION MARCH 2, 2023, 4:30 pm ET/ 22:30 CET MDxHealth Shareholder Transparency Declarations IRVINE, CA, and HERSTAL, BELGIUM - March [2], 2023 - MDxHealth SA (Nasdaq and Euronext Brussels: M
MDxHealth SA announced that it received shareholder transparency notifications relating to voting rights from MVM Partners, LLC and Biovest NV. MVM Partners, LLC reported a decrease in its stake to below 20% of the outstanding shares, while Biovest NV's holdings dropped below 5%. The changes stem from regulatory compliance under Belgian law and could influence governance dynamics within MDxHealth as it operates in the precision diagnostics sector for urologic cancers.
Read more →MDXHMDxHealth Reports Financial Year 2022 Results and Provides Business Update and Outlook for 2023
MDxHealth reported strong financial results for 2022, with revenues increasing by 67% to $37.1 million. The acquisition of the Genomic Prostate Score (GPS) test has strengthened the company's market position in precision diagnostics for prostate cancer. Despite these gains, MDxHealth also faced increased operating and net losses, which rose by 41% and 52% respectively. The company forecasts a revenue guidance of $65-$70 million for 2023, bolstered by enhanced coverage for their GPS test by UnitedHealthcare.
Read more →MDXHMDxHealth Announces Update of Outstanding Shares and Voting Rights
MDxHealth SA announced a successful capital increase, with share capital rising from EUR 160.66 million to EUR 163.47 million as of March 8, 2023. The company issued an additional 7.5 million shares, raising the total number of outstanding shares to 270.38 million. This update is part of the company's financial strategy and includes outstanding subscription rights that may further increase share counts in the future.
Read more →MDXHMDxHealth Announces Exercise of Option
MDxHealth SA announced the exercise of an underwriter option to purchase an additional 750,000 American Depositary Shares (ADSs) at $4.00 each. This exercise adds $3.0 million to the previously raised $40.0 million from an earlier public offering, resulting in total gross proceeds of $43.0 million. The closing of this additional transaction is expected on March 8, 2023, pending customary conditions. The new shares will have equal rights and benefits as existing shares.
Read more →MDXHMDxHealth Shareholder Transparency Declarations
MDxHealth has announced shareholder transparency declarations in compliance with Belgian regulatory requirements. The company reported that MVM Partners, LLC has reduced its voting rights to below 20% as of February 7, 2023, holding 17.31% of outstanding shares. Additionally, Biovest NV's voting rights have fallen below 5%, representing 4.54% of the shares. The changes in shareholding structures reflect shifts in management roles and could impact decision-making processes.
Read more →MDXHMDxHealth to Participate in 43rd Annual Cowen Healthcare Conference
MDxHealth SA announced that its CEO, Michael McGarrity, will present at the Cowen 43rd Annual Health Care Conference on March 6, 2023. This conference, taking place in Boston, MA, aims to feature various discussions around healthcare. A live webcast of the presentation will be accessible via the company's website, potentially reaching a wider audience interested in their precision diagnostics offerings.
Read more →MDXHREGULATED INFORMATION FEBRUARY 21, 2023, 4:30 pm ET/ 22:30 CET MDxHealth Shareholder Transparency Declaration IRVINE, CA, and HERSTAL, BELGIUM - 21 February 2023 - MDxHealth SA (Nasdaq and Euronext Brussel
MDxHealth SA announced a shareholder transparency declaration on February 21, 2023. The declaration revealed that Bleichroeder LP's voting rights crossed below 15% of the company's total outstanding shares. Specifically, they hold 14.75% of the 262,880,936 outstanding shares. The notification fulfills compliance requirements under the Belgian Transparency Act.
Read more →MDXHMDxHealth to Present Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
MDxHealth SA has announced that it will release its financial results for the fourth quarter and full year ending December 31, 2022, on March 8, 2023. The company has scheduled a conference call with live Q&A, providing an opportunity for stakeholders to engage with executives. This event will be accessible via webcast and phone for interested parties.
Read more →MDXHMDxHealth Announces Update of Outstanding Shares and Voting Rights and Update of Financial Calendar
MDxHealth SA has announced an update regarding its outstanding shares and voting rights, highlighting a capital increase completion that raised its share capital significantly. The number of issued shares has grown from approximately 162.9 million to 262.9 million due to the issuance of 100 million new shares. Additionally, the company updated its financial reporting calendar for 2023, detailing important upcoming dates for financial results and shareholder meetings.
Read more →MDXHMDxHealth Announces UnitedHealthcare to Provide Commercial Coverage for the Genomic Prostate Score (GPS) Test
MDxHealth SA announced that UnitedHealthcare will provide commercial coverage for its Genomic Prostate Score (GPS) test, the only such test covered for risk stratifying newly diagnosed men with localized prostate cancer. This coverage aims to assist in treatment decisions for eligible patients. The GPS test, an advanced 17-gene mRNA test, predicts tumor aggressiveness and offers insights into the likelihood of adverse outcomes. The recognition by UnitedHealthcare further expands the coverage already provided by other insurers, including Medicare.
Read more →MDXHFEBRUARY 2023, 4:00PM ET / 22:00 CET MDxHealth Announces UnitedHealthcare to Provide Commercial Coverage for the Genomic Prostate Score (GPS) Test UnitedHealthcare singles out mdxheath's GPS test as its o
MDxHealth announced that UnitedHealthcare will provide commercial coverage for its Genomic Prostate Score (GPS) test, the only covered test designated for risk stratification of newly diagnosed localized prostate cancer. This coverage is expected to boost the adoption of the GPS test, which utilizes a 17-gene signature to predict cancer aggressiveness and is already covered by other insurers. The CEO, Michael K. McGarrity, expressed enthusiasm over this designation, emphasizing its potential to enhance clinical outcomes for patients.
Read more →MDXHMDxHealth Announces Pricing of Offering of ADSs in the United States
MDxHealth has announced the pricing of a public offering of 10,000,000 American Depositary Shares (ADSs) at USD 4.00 each, aiming to raise USD 40.0 million before expenses. The underwriters have an option to purchase an additional 1,500,000 ADSs. The funds raised will be used for general corporate purposes, including product development and commercial activities. The offering is set to close on February 7, 2023, pending standard conditions.
Read more →MDXHMDxHealth Announces Launch of Offering of ADSs in the United States
MDxHealth has announced a proposed offering of $40 million worth of American Depositary Shares (ADSs) in the U.S. markets. The company will allow underwriters a 30-day option to purchase additional shares. The offering is contingent upon market conditions and comes with no guarantee of completion. Additionally, trading in MDxHealth's ordinary shares is currently suspended on Euronext Brussels pending this announcement.
Read more →MDXHREGULATED INFORMATION INSIDE INFORMATION FEBRUARY 1, 2023, 4PM ET/ 22:00 CET MDxHealth Announces Launch of Offering of ADSs in the United States IRVINE, CA, and HERSTAL, BELGIUM
MDxHealth announced the launch of a proposed offering of $40 million in American Depositary Shares (ADSs) in the United States. The offering is subject to market conditions and may not be completed as proposed. Notably, MDxHealth has halted trading of its ordinary shares on Euronext Brussels until the pricing of the offering is announced. Major underwriters involved in this offering include Cowen and Company and William Blair & Company, indicating potential strong interest from investors.
Read more →MDXHMDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test
MDxHealth has provided updated financial information regarding its acquisition of the Oncotype DX GPS test from Exact Sciences. The integration involved transitioning test ordering processes to MDxHealth's systems and restructuring its sales teams. The company also revealed a substantial increase in operating expenses due to the acquisition. Although the updated financial statements offer insight into the acquisition's financial impacts, MDxHealth faces challenges in realizing its anticipated benefits.
Read more →MDXHto Form 6-K with the Securities and Exchange Commission, updated unaudited pro forma combined financial information as of and for the six months ended
MDxHealth has released updated financial information related to its acquisition of the Oncotype DX GPS test from Exact Sciences. The information includes modifications in operating expenses and pro forma financial statements reflecting the integration of the GPS test into MDxHealth's operations. Despite some increases in operational costs due to the acquisition, the company's management expects substantial long-term benefits from the transaction. The update also addresses adjustments related to the new debt facility established alongside the acquisition.
Read more →MDXHMDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance
MDxHealth SA reported preliminary 2022 revenues of about $37 million and reaffirmed its 2023 revenue guidance of $65-$70 million. The CEO emphasized operational focus and improvements in reimbursement as key drivers for future growth. A significant acquisition from Exact Sciences enhances the company's position in personalized diagnostic solutions for urology. However, the preliminary financials are unaudited and could be subject to adjustments, with potential market risks highlighted.
Read more →MDXHINSIDE AND REGULATED INFORMATION 9 JANUARY 2023, 4PM ET / 22:00 CET MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM
MDxHealth has announced its preliminary revenues for 2022, estimating around $37 million, while reaffirming its revenue guidance for 2023 to be between $65 million and $70 million. The company highlighted its focus on improved reimbursement and an expanded diagnostic product offering. Additionally, MDxHealth's recent acquisition of the Genomic Prostate Score test enhances its position in the urology diagnostic market. However, the preliminary financial data may undergo material adjustments, and uncertainties due to the COVID-19 pandemic could pose risks to future operations.
Read more →MDXHMdxhealth files U.S. Shelf Registration on Form F-3
NEWS RELEASE – REGULATED INFORMATION December 19, 2022, 5:00PM EDT / 23:00 CET Mdxhealth files U.S. Shelf Registration on Form F-3 IRVINE, CA, and HERSTAL, BELGIUM – December 19, 2022 – Mdxhealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, tod
Read more →MDXHReport of Independent Auditors To the Management of Exact Sciences Corporation Opinion We have audited the accompanying special purpose combined financial statements of the Oncotype DX Prostate Score Test ("GPS"), a diag
Report of Independent Auditors To the Management of Exact Sciences Corporation the accompanying special purpose combined financial statements of the Oncotype DX Prostate Score Test ("GPS"), a diagnostic test offered by Exact Sciences Corporation, which comprises the special pu
Read more →MDXHMDxHealth Provides Business Update
NEWS RELEASE – INSIDE AND REGULATED INFORMATION 29 NOVEMBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Provides Business Update IRVINE, CA, and HERSTAL, BELGIUM – November 29, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today prov
Read more →MDXHINSIDE AND REGULATED INFORMATION 29 NOVEMBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Provides Business Update IRVINE, CA, and HERSTAL, BELGIUM
NEWS RELEASE - INSIDE AND REGULATED INFORMATION 29 NOVEMBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Provides Business Update IRVINE, CA, and HERSTAL, BELGIUM - November 29, 2022 - MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today pr
Read more →MDXHMDxHealth Reports Q3-2022 Results
NEWS RELEASE - REGULATED INFORMATION 27 OCTOBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q3-2022 Results IRVINE, CA, and HERSTAL, BELGIUM – October 27, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its fina
Read more →MDXHREGULATED INFORMATION 27 OCTOBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q3-2022 Results IRVINE, CA, and HERSTAL, BELGIUM
NEWS RELEASE - REGULATED INFORMATION 27 OCTOBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q3-2022 Results IRVINE, CA, and HERSTAL, BELGIUM - October 27, 2022 - MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its fi
Read more →MDXHINTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT 2 II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA 3 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER C
I. INTERIM MANAGEMENT REPORT 2 II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA 3 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 3 2. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION 4 3
Read more →MDXHMDxHealth Reports Half Year 2022 Results
NEWS RELEASE - REGULATED INFORMATION 25 AUGUST 2022, 4:00PM EDT, 22:00 CET MDxHealth Reports Half Year 2022 Results IRVINE, CA, and HERSTAL, BELGIUM – August 25, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostic
Read more →MDXHREGULATED INFORMATION 25 AUGUST 2022, 4:00PM EDT, 22:00 CET MDxHealth Reports Half Year 2022 Results IRVINE, CA, and HERSTAL, BELGIUM
MDxHealth Reports Half Year 2022 Results IRVINE, CA, and HERSTAL, BELGIUM - August 25, 2022 - MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today announced its financial results for the half year ended M
Read more →MDXHMdxhealth's New Share Capital Amount
NEWS RELEASE - REGULATED INFORMATION August 19, 2022, 4:00 PM EDT / 22:00 CET Mdxhealth's New Share Capital Amount and New Number of Shares IRVINE, CA, and HERSTAL, BELGIUM - August 19, 2022 - MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commerci
Read more →MDXHAcquires Oncotype DX GPS Prostate Cancer Business
Acquires Oncotype DX GPS Prostate Cancer Business and Reports Preliminary Half Year 2022 Results Conference Call and Webcast Today at 4:30PM IRVINE, CA, and HERSTAL, BELGIUM - August 2, 2022 - MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-s
Read more →MDXHMdxhealth Acquires Oncotype DX GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results
NEWS RELEASE – INSIDE AND REGULATED INFORMATION August 2, 2022, 4:00PM EDT / 22:00 CET Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results Solidifies leadership in the precision diagnostics urology ma
Read more →MDXHREGULATED INFORMATION 25 May 2022, 4:00 p.m. EDT / 22:00 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders' Meetings and Resignation of Director IRVINE, CA, and HERSTAL,
NEWS RELEASE - REGULATED INFORMATION 25 May 2022, 4:00 p.m. EDT / 22:00 CET MDxHealth Announces Results of its Annual and General Shareholders' Meetings and Resignation IRVINE, CA, and HERSTAL, BELGIUM - 25 May 2022 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) ("MDxH
Read more →MDXHMDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings and Resignation of Director
NEWS RELEASE - REGULATED INFORMATION 25 May 2022, 4:00 p.m. EDT / 22:00 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings and Resignation of Director IRVINE, CA, and HERSTAL, BELGIUM – 25 May 2022 – MDxHealth SA (Nasdaq and Euronex
Read more →MDXHPalmetto GBA's MolDX Issues Foundational
NEWS RELEASE - REGULATED INFORMATION May 19, 2022, 4:00PM EDT / 22:00 CET Palmetto GBA's MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer IRVINE, CA, and HERSTAL, BELGIUM - May 19, 2022 - - MDxHealth SA (NASDAQ/Euronext: MDXH), a commer
Read more →MDXHREGULATED INFORMATION 27 APRIL 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q1-2022 Results IRVINE, CA, and HERSTAL, BELGIUM
NEWS RELEASE - REGULATED INFORMATION 27 APRIL 2022, 4:00PM EDT / 22:00 CET Reports Q1-2022 Results CA, and HERSTAL, BELGIUM - April 27, 2022 - MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its financial results for th
Read more →MDXHMDxHealth Reports Q1-2022 Results
NEWS RELEASE - REGULATED INFORMATION 27 APRIL 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q1-2022 Results IRVINE, CA, and HERSTAL, BELGIUM – April 27, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its financia
Read more →MDXHMDxHealth to Participate in the 14th Annual Kempen Life Sciences Conference
March 30, 2022, 4:30 PM EST / 22:30 CET MDxHealth to Participate in the 14th Annual Kempen Life Sciences Conference IRVINE, CA, and HERSTAL, BELGIUM – March 30, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that M
Read more →MDXHREGULATED INFORMATION 2 MARCH 2022, 4:00 PM EST / 22:00 CET MDxHealth Reports Financial Year 2021 Results and Provides Outlook and Guidance for 2022 Conference call with Q&A today at 4:30 PM EST / 22:30 CE
Financial Year 2021 Results Outlook and Guidance for 2022 Conference call with Q&A today at 4:30 IRVINE, CA, and HERSTAL, BELGIUM - March 2, 2022 - MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its financial results f
Read more →MDXHMDxHealth Reports Financial Year 2021 Results and Provides Outlook and Guidance for 2022
NEWS RELEASE - REGULATED INFORMATION 2 MARCH 2022, 4:00 PM EST / 22:00 CET MDxHealth Reports Financial Year 2021 Results and Provides Outlook and Guidance for 2022 Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 2, 2022 – MD
Read more →MDXHMDxHealth to Present Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 2nd
17 February 2022, 4:00 PM EST / 22:00 CET MDxHealth to Present Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 2nd Company to Host Conference Call with Live Q&A, March 2, 2022 at 4:30pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – Februar
Read more →MDXHMDxHealth to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
9 FEBRUARY 2022, 4:00 PM EST / 22:00 CET MDxHealth to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference IRVINE, CA, and HERSTAL, BELGIUM – February 9, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics compan
Read more →MDXHREGULATED INFORMATION 10 December 2021, 23:55 CET MDxHealth Shareholder Transparency Declaration IRVINE, CA, and HERSTAL, BELGIUM - 10 December 2021 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the
NEWS RELEASE - REGULATED INFORMATION 10 December 2021, 23:55 MDxHealth Shareholder Transparency Declaration IRVINE, CA, and HERSTAL, BELGIUM - 10 December 2021 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage precision di
Read more →MDXHREGULATED INFORMATION 22 November 2021, 11:00 p.m. CET MDxHealth Shareholder Transparency Declarations IRVINE, CA, and HERSTAL, BELGIUM - 22 November 2021 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH
NEWS RELEASE - REGULATED INFORMATION22 November 2021, 11:00 p.m. CET MDxHealth Shareholder Transparency Declarations IRVINE, CA, and HERSTAL, BELGIUM - 22 November 2021 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage prec
Read more →MDXHMDxHealth Announces Completion of Initial Public Offering of ADSs in the United States
NEWS RELEASE – REGULATED INFORMATION 15 November 2021, 11:00 p.m. CET MDxHealth Shareholder Transparency Declarations IRVINE, CA, and HERSTAL, BELGIUM – 15 November 2021 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage prec
Read more →MDXHREGULATED INFORMATION 15 November 2021, 11:00 p.m. CET MDxHealth Shareholder Transparency Declarations IRVINE, CA, and HERSTAL, BELGIUM - 15 November 2021 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH
RELEASE - REGULATED INFORMATION November 2021, 11:00 p.m. CET Shareholder Transparency Declarations CA, and HERSTAL, BELGIUM - 15 November 2021 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage precision diagnostics company
Read more →MDXHREGULATED INFORMATION NOVEMBER 8, 2021, 22:30 CET MDxHealth Announces Completion of Initial Public Offering of ADSs in the United States IRVINE, CA, and HERSTAL, BELGIUM
NEWS RELEASE - REGULATED INFORMATION NOVEMBER 8, 2021, 22:30 CET Announces Completion of Initial Public Offering of ADSs CA, and HERSTAL, BELGIUM - November 8, 2021 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), a commercial-stage precis
Read more →MDXHMDxHealth Announces Pricing of Initial Public Offering of ADSs in the United States
NEWS RELEASE - REGULATED INFORMATION 4 NOVEMBER 2021, 13:00 CET MDxHealth Announces Pricing of Initial Public Offering of ADSs in the United States IRVINE, CA, and HERSTAL, BELGIUM – November 4, 2021 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) ("MDxHealth" or the "Com
Read more →MDXHMDxHealth Announces Launch of Proposed Initial Public Offering of ADSs in the United States
NEWS RELEASE - REGULATED INFORMATION 28 OCTOBER 2021, 07:00 CEST MDxHealth Announces Launch of Proposed Initial Public Offering of ADSs in the United States IRVINE, CA, and HERSTAL, BELGIUM – October 28, 2021 – MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Compa
Read more →MDXHMDxHealth Provides Q3-2021 Business Update
NEWS RELEASE - REGULATED INFORMATION 21 OCTOBER 2021, 07:00 A.M. CET MDxHealth Provides Q3-2021 Business Update IRVINE, CA, and HERSTAL, BELGIUM – October 21, 2021 – MDxHealth SA (Euronext: MDXH.BR) (“MDxHealth” or the “Company”), a commercial-stage precision diagnostics compa
Read more →MDXHMDxHealth files Registration Statement for Proposed Initial Public Offering in the United States
NEWS RELEASE - REGULATED INFORMATION 13 OCTOBER 2021, 19:30 CET MDxHealth files Registration Statement for Proposed Initial Public Offering in the United States IRVINE, CA, and HERSTAL, BELGIUM – October 13, 2021 – MDxHealth SA (Euronext: MDXH.BR) ("MDxHealth" or the "Company
Read more →MDXHMDxHealth Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States
NEWS RELEASE - REGULATED INFORMATION September 1, 2021, 18:00 CEST MDxHealth Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States IRVINE, CA, and HERSTAL, BELGIUM – September 1, 2021 – MDxHealth SA (Euronext Brussels: MDXH) ("M
Read more →MDXHMDxHealth Reports Half Year 2021 Results
NEWS RELEASE - REGULATED INFORMATION 26 AUGUST 2021, 18:00 CET MDxHealth Reports Half Year 2021 Results Conference call with Q&A today at 19:00 CET / 1PM US ET, details provided below IRVINE, CA, and HERSTAL, BELGIUM – August 26, 2021 – MDxHealth SA (Euronext: MDXH.BR), a com
Read more →MDXHMDxHealth to Present First Half 2021 Financial Results and Corporate Update on August 26
Company to Host Conference Call and Live Q&A Session, August 26, 2021, at 10:00am PT/ 1:00pm ET/ 19:00 CET IRVINE, CA, and HERSTAL, BELGIUM – August 12, 2021, 1:00 AM (CET)– MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative precision diagnostics company, today anno
Read more →MDXHMDxHealth Announces Favorable Draft Medicare Coverage for the SelectMDx for Prostate Cancer Test
IRVINE, CA, and HERSTAL, BELGIUM – 07:00 CET May 21, 2021 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth") a commercial-stage innovative molecular diagnostics company, announces that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses mol
Read more →MDXHMDxHealth announces listing of 9,639,489 existing shares on Euronext Brussels following the January 2021 Capital Increase
NEWS RELEASE – REGULATED INFORMATION 21 April 2021, 10:00 p.m. CET IRVINE, CA, and HERSTAL, BELGIUM – 21 April 2021 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth") a commercial-stage innovative molecular diagnostics company, announces today that 9,639,48
Read more →MDXHMDxHealth Provides Q1-2021 Business Update
NEWS RELEASE - REGULATED INFORMATION 21 APRIL 2021, 07:00 A.M. CET IRVINE, CA, and HERSTAL, BELGIUM – April 21, 2021 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today provided a business update for the first quarter ended Mar
Read more →MDXHMDxHealth Reports Financial Year 2020 Results and Provides Outlook for 2021
NEWS RELEASE - REGULATED INFORMATION 3 MARCH 2021, 07:00 A.M. CET Conference call with Q&A today at 08:00 CET / 07:00 GMT, details provided below IRVINE, CA, and HERSTAL, BELGIUM – March 3, 2021 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnos
Read more →MDXHMDxHealth's New Share Capital Amount and New Number of Shares
NEWS RELEASE – REGULATED INFORMATION 26 January 2021, 06:00 p.m. CET IRVINE, CA, and HERSTAL, BELGIUM – 26 January 2021 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, announces, in accordance
Read more →MDXHMDxHealth Successfully Completes a EUR 25.0 Million (USD 30.4 Million)(1) Capital Increase
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW NEWS RELEASE – REGULATED INFORMATION – INSIDE INFORMATION 21
Read more →MDXHMDxHealth Launches Capital Increase and Provides Preliminary 2020 Financial Results
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW NEWS RELEASE – REGULATED INFORMATION – INSIDE INFORMATION 21
Read more →MDXHMDxHealth Provides Q3-2020 Business Update
NEWS RELEASE - REGULATED INFORMATION 21 OCTOBER 2020, 07:00 A.M. CEST IRVINE, CA, and HERSTAL, BELGIUM – October 21, 2020 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today provided a business update for the third quarter ended
Read more →MDXHMDxHealth announces listing of 20,162,924 existing shares on Euronext Brussels following Equity Investment by MVM Partners
Press release Regulated information. 16 October 2020, 07:00 a.m. CEST IRVINE, CA, and HERSTAL, BELGIUM – 16 October 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth") a commercial-stage innovative molecular diagnostics company, announces today that 20,1
Read more →MDXHMDxHealth Reports Half Year 2020 Results
Conference call with Q&A today at 08:00 CET / 07:00 GMT, details provided below IRVINE, CA, and HERSTAL, BELGIUM – August 26, 2020 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced its financial results for the half
Read more →MDXHMDxHealth to Report Half Year 2020 Results on Wednesday, August 26, 2020
IRVINE, CA, and HERSTAL, BELGIUM – August 20, 2020 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced that it will release its financial and operating results for the half-year ended June 30, 2020, on Wednesday, August
Read more →MDXHMDxHealth Provides Update on Medicare Coverage for SelectMDx
Press Release Regulated Information Inside Information August 7, 2020, 7:00 CET IRVINE, CA and HERSTAL, BELGIUM – August 7, 2020 – MDxHealth SA (Euronext Brussels: MDXH), a commercial-stage innovative molecular diagnostics company, today reports an update and associated delay i
Read more →MDXHMDxHealth Announces Results of Special and Extraordinary General Shareholders' Meetings
Press release Regulated information 30 July 2020, 17:00 CEST IRVINE, CA, and HERSTAL, BELGIUM – 30 July 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, today held a special general shar
Read more →MDXHMDxHealth (R):
Press Release 27 July 2020, 7:00 CET MDxHealth Announces Inclusion of SelectMDx in 2020 NCCN Guidelines for Prostate Cancer Early Detection IRVINE, CA – June 27, 2020 – MDxHealth, a commercial-stage innovative molecular diagnostics company, today announced that its SelectMDx
Read more →MDXHMDxHealth Announces its Special and Extraordinary General Shareholders’ Meetings
Press release Regulated information 30 June 2020, 7:30 a.m. CEST IRVINE, CA, and HERSTAL, BELGIUM – 30 June 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth") a commercial-stage innovative molecular diagnostics company, today invites the holders of secu
Read more →MDXHMDxHealth Announces Results of Annual and Extraordinary General Shareholders' Meetings
Press release Regulated information 28 May 2020, 11:00 p.m. CEST IRVINE, CA, and HERSTAL, BELGIUM – 28 May 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, today held its annual general sh
Read more →MDXHMDxHealth Completes the Equity Investment by MVM Partners
Press release Regulated information IRVINE, CA, and HERSTAL, BELGIUM – 15 May 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, announces today that MVM V LP and MVM GP (No.5) LP, funds mana
Read more →MDXHMDxHealth Announces its Annual and Extraordinary General Shareholders’ Meetings
Regulated information – Inside information 28 April 2020, 7:30 a.m. CEST IRVINE, CA, and HERSTAL, BELGIUM – 27 April 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth") a commercial-stage innovative molecular diagnostics company, today invites the holde
Read more →MDXHMDxHealth Announces Growth Investment from MVM Partners
Regulated information – Inside information IRVINE, CA, and HERSTAL, BELGIUM – 27 April 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth") a commercial-stage innovative molecular diagnostics company, announces today that it entered into a subscription ag
Read more →MDXHMDxHealth to Receive $2.3 million “Paycheck Protection Program” Loan Under the U.S. CARES Act
IRVINE, CA, and HERSTAL, BELGIUM – April 20, 2020 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced that its U.S. subsidiary, MDxHealth Inc., has entered into a “Paycheck Protection Program” (PPP) loan with the U.S. S
Read more →MDXHMDxHealth Provides Q1-2020 Business Update
PRESS RELEASE REGULATED INFORMATION IRVINE, CA, and HERSTAL, BELGIUM – April 9, 2020 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today provided a business update for the first quarter ended March 31, 2020. Michael McGarrity,
Read more →MDXHMDxHealth Updates 2020 Reporting Calendar and Provides Initial View on Coronavirus Situation
IRVINE, CA, and HERSTAL, BELGIUM – April 1, 2020 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today updated its 2020 reporting calendar, moving its Q1 business update forward to April 9th from April 21st. 2020 Reporting Calenda
Read more →MDXHMDxHealth Reports Financial Year 2019 Results and Provides Outlook for 2020
Conference call with Q&A today at 09:00 CET / 08:00 GMT, details provided below IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2020 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced its financial results for the yea
Read more →MDXHMDxHealth Provides Q3-2019 Business Update
IRVINE, CA, and HERSTAL, BELGIUM – November 11, 2019 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today provided a business update for the three and nine months ended September 30, 2019. Michael McGarrity, CEO of MDxHealth, sai
Read more →MDXHMDxHealth Successfully Completes a EUR 9.0 Million (USD 9.8 Million)(1) Capital Increase
Regulated information – Inside information 27 September 2019, 6:00 a.m. CEST IRVINE, CA, and HERSTAL, BELGIUM – 27 September 2019 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, announces the
Read more →MDXHMDxHealth Launches Capital Increase and Secures Debt Financing from Kreos Capital
Regulated information – Inside information 26 September 2019, 2:00 p.m. CEST IRVINE, CA, and HERSTAL, BELGIUM – 26 September 2019 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, announces the
Read more →MDXHMDxHealth Reports Half Year 2019 Financial Results and Strategic Update
Conference call with Q&A today at 11:00 CEST / 10:00 BST, details provided below IRVINE, CA, and HERSTAL, BELGIUM– August 29, 2019 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced its financial results for the half
Read more →MDXHMDxHealth (R): MDxHealth Announces Favorable Draft Medicare Coverage for the SelectMDx Test
IRVINE, CA – August 26, 2019 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDx program, has
Read more →MDXHMDxHealth: MDxHealth Notice of Interim Results 2019
REGULATED INFORMATION Conference call for analysts and investors to be held on 29 August 2019 at 11.00 CEST IRVINE, CA, and HERSTAL, BELGIUM – 07.00 CEST, 23 August 2019 – MDxHealth SA (Euronext: MDXH.BR) or the “Company” today announced that it will release its interim results
Read more →MDXHMDxHealth (R): Extraordinary General Shareholders’ Meeting
NEWS RELEASE REGULATED INFORMATION Extraordinary General Shareholders’ Meeting IRVINE, CA, and HERSTAL, BELGIUM – 18:00 CET, June 21, 2019 – MDxHealth SA (Euronext: MDXH) held today its Extraordinary Ge
Read more →MDXHMDxHealth (R): Multi-center Study Validates SelectMDx's High Negative Predictive Value and Sensitivity
Multi-center 1,955 patient study published in the Journal of Urology IRVINE, CA, and HERSTAL, BELGIUM - Jun 10, 2019 - MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced that a second clinical validation study demonstra
Read more →MDXHMDxHealth (R): Annual General Shareholders’ Meeting
NEWS RELEASE REGULATED INFORMATION Annual General Shareholders’ Meeting IRVINE, CA, and HERSTAL, BELGIUM – [18:00 CEST], May 29, 2019 – MDxHealth SA (Euronext: MDXH) held today its Annual General Shareho
Read more →MDXHMDxHealth: Presentation of New Data for MDxHealth's Prostate Cancer Diagnostic Tests at AUA 2019 Annual Meeting
Moderated posters feature clinical validations of SelectMDx and ConfirmMDx IRVINE, CA, and HERSTAL, BELGIUM - MAY 3, 2019 - MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced that positive data demonstrating the clinica
Read more →MDXHMDxHealth (R): MDxHealth provides Q1 2019 business update
NEWS RELEASE REGULATED INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - April 24, 2019 - MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today provided a business update for the first quarter ended March 31, 2019. Michael K. McGarrit
Read more →MDXHMDxHealth (R): MDxHealth Announces Positive Data from Pan-European Clinical Validation Study of SelectMDx
SelectMDx demonstrates accurate identification of both low-risk and aggressive prostate cancer across all patient groups IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CET, March 18, 2019 - MDxHealth SA (Euronext: MDXH.BR) today announces that positive data from a pre-biopsy clinical
Read more →MDXHMDxHealth : SelectMDx Liquid Biopsy Test for Prostate Cancer Included in the 2019 Italian Society of Urology Guidelines
MDxHealth's SelectMDx ® Liquid Biopsy Test for Prostate Cancer Included in the 2019 Italian Society of Urology Guidelines A significant milestone to increase adoption of SelectMDx in Italy IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CET, March 5, 2019 - MDxHealth SA (Euronext: MDX
Read more →MDXHMDxHealth (R): MDxHealth Reports Financial Year 2018 Results and Provides Outlook for 2019
NEWS RELEASE REGULATED INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, February 28, 2019 - MDxHealth SA (Euronext: MDXH.BR), today announced its business update and financial results for the year ended December 31, 2018 and provided its strategic outlook for 2019.
Read more →MDXHMDxHealth (R): MDxHealth Appoints Michael K. McGarrity as CEO
NEWS RELEASE REGULATED INFORMATION INSIDE INFORMATION February 19, 2019 - 07:00 CET Dr. Jan Groen continues as an advisor to the Board IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CET, February 19, 2019 - MDxHealth SA (Euronext: MDXH.BR), today announced the appointment of Mich
Read more →MDXHMDxHealth (R): MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis
Data to be Presented at the Annual ASCO Genitourinary Cancers Symposium Data to further support clinical adoption of SelectMDx and ConfirmMDx IRVINE, CA, and HERSTAL, BELGIUM - February 15, 2019 - MDxHealth SA (Euronext: MDXH.BR) today announced that positive data and observati
Read more →MDXHMDxHealth (R): MDxHealth Signs Partnership with LifeLabs to Make SelectMDx available in Canada
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CET, February 14, 2019 - MDxHealth SA (Euronext: MDXH.BR) today announces that it has signed an exclusive distribution agreement with LifeLabs to make SelectMDx®, the Company's non-invasive liquid biopsy prostate cancer test, available in
Read more →MDXHMDxHealth (R): MDxHealth Shareholder Transparency Declaration
NEWS RELEASE REGULATED INFORMATION HERSTAL, BELGIUM and IRVINE, CA - February 9, 2019 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), announced that it received on February 7, 2019 the following notification of significant shareholdings in accordance wi
Read more →MDXHMDxHealth (R): SelectMDx Outperforms Prostate Health Index (phi) Blood Test for Detecting High-Grade Prostate Cancer
NEWS RELEASE REGULATED INFORMATION Data to be presented at the 29th Annual IPCU meeting Beaver Creek, Co, January 24-27, 2019 IRVINE, CA, and HERSTAL, BELGIUM - January 24, 2019 - MDxHealth SA (Euronext: MDXH.BR) today announced data to be presented at the 29th Annual Interna
Read more →MDXHMDxHealth (R): MDxHealth Provides Business Update
NEWS RELEASE REGULATED INFORMATION INSIDE INFORMATION January 14, 2019 - 07:00 CET Preliminary 2018 financial results Total genomic test volumes up 16% Implemented operational cost reduction of ~$10 Million IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CET, January 14, 2019 - MDx
Read more →MDXHMDxHealth (R): MDxHealth Announces Approval for SelectMDx for Prostate Cancer by New York State
NEWS RELEASE REGULATED INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07.00 CET, 26 November 2018 - MDxHealth SA (Euronext: MDXH.BR) today announces that the New York State Department of Health has approved its SelectMDx test for Prostate Cancer. This completes MDxHealth's stat
Read more →MDXHMDxHealth (R): SelectMDx improves prostate biopsy decision-making in urology practices
NEWS RELEASE REGULATED INFORMATION Real-world study shows that SelectMDx helps urologists more confidently determine the need for an initial prostate biopsy IRVINE, CA, and HERSTAL, BELGIUM - 07.00 CEST, 7 November 2018 - MDxHealth SA (Euronext: MDXH.BR) or the "Company" today
Read more →MDXHMDxHealth Provides Business Update for the first nine months of 2018
NEWS RELEASE REGULATED INFORMATION INTERIM TRADING UPDATE Product and Service revenue up 29% year-on-year IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, October 23, 2018 - MDxHealth SA ("MDxHealth, or the "Company"), (Euronext: MDXH.BR), today issued its business update for t
Read more →MDXHMDxHealth Shareholder Transparency Declaration MDxHealth (R):
Press release Regulated information 17 October 2018, 7.00 p.m. CET HERSTAL, BELGIUM and IRVINE, CA - October 17, 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), announced that it received on October 12, 2018 the following notification of significan
Read more →MDXHMDxHealth (R): MDxHealth Reports Half Year 2018 Results
NEWS RELEASE REGULATED INFORMATION INTERIM FINANCIAL REPORT Good Operational Progress and Healthy Double-Digit Growth of Clinical Testing Volumes Conference call for analysts and investors today at 15:00 CET / 09:00 EST, details below IRVINE, CA, and HERSTAL, BELGIUM - 07
Read more →MDXHMDxHealth (R): SelectMDx Cost-effective in Four European Countries
NEWS RELEASE REGULATED INFORMATION Potential healthcare cost savings in France, Germany, Italy and Spain of over €300 million IRVINE, CA, and HERSTAL, BELGIUM - 07.00 CEST, 28 August 2018 - MDxHealth SA (Euronext: MDXH.BR) worldwide leading in molecular diagnostics for urologi
Read more →MDXHMDxHealth (R) : MDxHealth Notice of Interim Results 2018
NEWS RELEASE REGULATED INFORMATION Conference call for analysts and investors to be held on 30 August 2018 at 15:00 CEST IRVINE, CA, and HERSTAL, BELGIUM - 08.00 CEST, 10 August 2018 - MDxHealth SA (Euronext: MDXH.BR) or the "Company" today announced that it will release its
Read more →MDXHMDxHealth: SelectMDx Study Demonstrates Cost-effectiveness in US Healthcare System
NEWS RELEASE REGULATED INFORMATION Data published in Journal of Urology reports over $500 million in potential annual cost savings for the US healthcare system IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, July 31, 2018 - MDxHealth SA (Euronext: MDXH.BR) today announces that
Read more →MDXHMDxHealth (R): Medicare Establishes Final Positive Local Coverage Determination for Use of ConfirmMDx for Prostate Cancer
Providing Nationwide Coverage for Medicare Patients IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, July 23, 2018 - MDxHealth SA (Euronext: MDXH.BR), today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has
Read more →MDXHMDxHealth's SelectMDx Test Successfully Stratifies Men
MDxHealth's SelectMDx Test Successfully Stratifies Men Who May Benefit from mp-MRI Multiple SelectMDx Clinical Study Abstracts presented at 2018 Global Prostate Congress in Frankfurt, Germany HERSTAL, BELGIUM and IRVINE, CA - 07:00 CEST, June 27, 2018 - MDxHealth SA (Euronext B
Read more →MDXHMDxHealth launch agreement with Philips for prognostic prostate cancer biomarker
MDxHealth announces worldwide licencing agreement with Philips for prognostic prostate cancer biomarker Agreement with Philips facilitates the launch of InformMDx(TM) HERSTAL, BELGIUM and IRVINE, CA - 07:00 CEST, June 6, 2018 - MDxHealth SA ("MDxHealth, or the "Company"), (Eur
Read more →MDXHMDxHealth (R): Presentation of New Data on MDxHealth's Prostate and Bladder Cancer Products at AUA 2018 Annual Meeting
Moderated posters and oral presentations feature clinical and health economic validations of SelectMDx, ConfirmMDx and prospective clinical validation of AssureMDx IRVINE, CA, and HERSTAL, BELGIUM - 07.00 CEST, May 22, 2018 - MDxHealth SA (Euronext: MDXH.BR) announces that signi
Read more →MDXHMDxHealth releases 2017 Annual Report
NEWS RELEASE REGULATED INFORMATION MDxHealth releases 2017 Annual Report and invitation to its Annual General Shareholders' Meeting IRVINE, CA, and HERSTAL, BELGIUM - 17:45 CEST, April 27, 2
Read more →MDXHMDxHealth Announces Positive Clinical Updates for ConfirmMDx
NEWS RELEASE REGULATED INFORMATION MDxHealth Announces Positive Clinical Updates for ConfirmMDx ConfirmMDx included in the 2018 EAU Guidelines for Prostate Cancer Publication of ConfirmMDx
Read more →MDXHMDxHealth Provides First Quarter 2018
NEWS RELEASE REGULATED INFORMATION INTERIM TRADING UPDATE MDxHealth Provides First Quarter 2018 Business Update IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, April 24, 2018 - MDxHealth SA
Read more →MDXHMDxHealth (R): SelectMDx Included in Dutch DRG Reimbursement System
Further progress of strategy to expand market for SelectMDx® IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, April 20, 2018 - MDxHealth SA ("MDxHealth, or the "Company"), (Euronext: MDXH.BR), a world leader in molecular diagnostics for urological cancers, today announced the incl
Read more →MDXHMDxHealth (R): Denominator PR
Regulated information 29 March 2018, 7 a.m. CET MDxHealth's New Share Capital Amount and New Number of Shares IRVINE, CA, and HERSTAL, BELGIUM - 29 March 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), a world leader in molecular diagnostics for
Read more →MDXHMDxHealth (R): MDxHealth Successfully Completes a EUR 36 Million (USD 44 million)(1) Capital Increase
Press release - Regulated information - Inside information - 22 March 2018, 8.00 a.m.CET IRVINE, CA, and HERSTAL, BELGIUM - 22 March 2018 - MDxHealth SA (Euronext Brussels: MDXH), a world leader in molecular diagnostics for urological cancers, announces the successful pricing of
Read more →MDXHMDxHealth (R): MDxHealth Launches Capital Increase
Press release - Regulated information - Inside information - 21 March 2018, 5:45 p.m. CET IRVINE, CA, and HERSTAL, BELGIUM - 21 March 2018 - MDxHealth SA (Euronext Brussels: MDXH) a world leader in molecular diagnostics for urological cancers, announces the launch of a capital i
Read more →MDXHMDxHealth (R): SelectMDx Liquid Biopsy Test for Prostate Cancer included in the 2018 European Association Urology Guidelines
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION A significant milestone in MDxHealth's strategy to increase adoption of SelectMDx® HERSTAL, BELGIUM and IRVINE, CA - 07:00 CEST, March 19, 2018 - MDxHealth SA (Euronext Brussels: MDXH.BR), a world leader in molecular dia
Read more →MDXHMDxHealth contract SelectMDx with Roman Hospital
MDxHealth enters into commercial agreement for SelectMDx with Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata Hospital in Rome HERSTAL, BELGIUM and IRVINE, CA - 07:00 CEST, February 28, 2017 - MDxHealth SA (Euronext: MDXH.BR ) a world-leading player in the
Read more →MDXHMDxHealth Notice of Financial Year 2017 Results
COMPANY ANNOUNCEMENT REGULATED INFORMATION MDxHealth Notice of Financial Year 2017 Results Conference call for analysts and investors to be held on 22 February 2018 at 15:00 CET IRVINE, CA, and HERSTAL, BELGIUM -
Read more →MDXHMDxHealth (R): Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients
NEWS RELEASE/REGULATED INFORMATION/INSIDE INFORMATION Study demonstrates test can add prognostic information on overall survival Earlier assessment of treatment response can help identify resistance sooner Over 233,000 CRPC patients under treatment globally each year HERSTAL,
Read more →MDXHMDxHealth: Shareholder Transparency Declaration
REGULATED INFORMATION MDxHealth: Shareholder Transparency Declaration HERSTAL, BELGIUM and IRVINE, CA- January 17, 2018 - MDxHealth SA (Euronext: MDXH.BR) today announced that, that it received the following notification of significant shareholdings, in conformity with Article
Read more →MDXHMDxHealth (R): MDxHealth Announces Lowering of 2017 Guidance
HERSTAL, BELGIUM and IRVINE, CA - December 28, 2017 - MDxHealth SA (Euronext: MDXH.BR, "MDxHealth", or the "Company"), a world leader in molecular diagnostic prostate cancer testing, today announced that, based on preliminary results for the fourth quarter, the Company will not m
Read more →MDXHMDxhealth teams up with Pharmaceutical Company Ferrer for distribution of its Prostate Cancer test SelectMDx in Spain
Promising market with an estimate of over 300.000 Spanish men with elevated PSA levels MDxHealth's urine test a non-invasive, molecular test clearly showing who could safely forego a painful biopsy, saving patients from over diagnosis and over treatment NEWS RELEASE / REGULATE
Read more →MDXHMDxHealth Nine Month Trading Update
Patient test volume for the first nine months up 43% SelectMDx test volume in Europe increased nearly 400% NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CET, November 2, 2017 - MDxHealth SA (Euronext: MDXH.BR) today issued i
Read more →MDXHMDxhealth Enters into Distribution Agreement with Unilabs for SelectMDx for Prostate Cancer
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, October 30, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that the company has entered into an agency service agreement for SelectMDx® with Swiss-based Unilabs, one
Read more →MDXHMDxHealth Opens New Service and Research Laboratory in The Netherlands
COMPANY ANNOUNCEMENT HERSTAL, BELGIUM - 07:00 CEST, October 5, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced the opening of its new service and research laboratory at the Novio Tech Campus in Nijmegen, the Netherlands. MDxHealth has leased 700 square meters of prime m
Read more →MDXHMDxHealth Prepares for Growth with Executive Team Expansion
Michael K. Brawer, MD Appointed as Chief Medical Officer PRESS RELEASE / REGULATED INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, September 6, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced the appointment of Michael K. Brawer, MD as Chief Medical Officer i
Read more →MDXHMDxHealth Announces First Half 2017 Financial Results
Total revenue up 87%, product revenue up 10% and 44% increase in test volume NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 31, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced financial results for the fir
Read more →MDXHMDxHealth Notice of January-June 2017 Financial Results
COMPANY ANNOUNCEMENT / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 16, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that it will release its financial results for the first half of the year ended December 31, 2017 o
Read more →MDXHMDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group
COMPANY ANNOUNCEMENT / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 8, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced it has signed a health care services agreement with Southern California Permanente Medical Group to
Read more →MDXHMDxHealth Appoints Seasoned EVP to Lead Sales Force Expansion
COMPANY ANNOUNCEMENT / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 7, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced the appointment of Paul Marr as Executive Vice President of Sales for North America in conjunction
Read more →MDXHMDxHealth to Participate in Canaccord Genuity Growth Conference
COMPANY ANNOUNCEMENT / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 2, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that it will participate in the 37th Annual Canaccord Genuity Growth Conference to be held at the In
Read more →MDXHMDxHealth Launches AssureMDx for Bladder Cancer Liquid Biopsy Test
Study reports test could reduce invasive diagnostic procedures by 77% NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, July 6, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced the commercial launch of its AssureMD
Read more →MDXHMDxHealth Presents Three SelectMDx Studies at 5th Global Congress on Prostate Cancer
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, June 28 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced its activities at the fifth Global Congress on Prostate Cancer in Lisbon, Portugal (June 28-30) with presentat
Read more →MDXHMDxHealth and Queensland University of Technology Collaborate on Oral Cancer Liquid Biopsy Test
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, June 19, 2017 - MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a scientific agreement with QUT bluebox, the commercialization arm of the Queensland Uni
Read more →MDXHMDxHealth Launches CE-Marked SelectMDx IVD PCR Kit and UrNCollect Device
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION / FOR EX-US ONLY IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, June 08, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced the launch in Europe and other markets* of the SelectMDx® for Prostate Cancer in vitro diag
Read more →MDXHMDxHealth Shareholder Transparency Notification
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00AM CEST, May 16 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that it received the following notification of significant shareholdings, in conformity with Article 15 of th
Read more →MDXHMDxHealth Trading Update: January to April 2017
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, May 8, 2017 - MDxHealth SA (Euronext: MDXH.BR) today issued its first trading update for the year summarizing commercial, R&D and financial highlights for the four months en
Read more →MDXHMDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, May 5, 2017 - MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed an agreement with the Faculty of Health, Medicine and Life Sciences / School for Oncology a
Read more →MDXHMDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, May 2, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that MediNcrease Health Plans, a national provider network in the US, has signed a contract to make ConfirmMDx®
Read more →MDXHMDxHealth and Exact Sciences Sign Collaboration Agreement
Exact Sciences also to acquire biomarker and technology patents NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, April 27, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that it has signed a five-year agreement wi
Read more →MDXHMDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CET, April 4, 2017 - MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed an exclusive licensing deal with Ghent University in Belgium for its proprietary molecular
Read more →MDXHMDxHealth Epigenetic Biomarkers Identify Men at Increased Risk of Prostate Cancer Recurrence
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION ABSTRACT #490, POSTER SESSION 36 Data presented at EAU 2017 shows potential to improve personalized treatment IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CET, March 27, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announ
Read more →MDXHMDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - March 21, 2017 - MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a distribution agreement to make its SelectMDx(TM) for Prostate Cancer test available to Lab21 Clini
Read more →MDXHMDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - February 23, 2017 - MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a distribution agreement to make its SelectMDx(TM) for Prostate Cancer test available to Istituto
Read more →MDXHMDxHealth Reports Financial Year 2016 Results
NEWS RELEASE REGULATED INFORMATION INSIDE INFORMATION Record revenue of $30 million, up 70% from 2015 Total test volume up 57% over 2015 Conference call for analysts and investors today at 15:00 CET / 09:00 EST, details below IRVINE, CA, and HERSTAL, BELGIUM - 7:00 AM, Feb
Read more →MDXHMDxHealth Notice of Financial Year 2016 Results
Conference call for analysts and investors to be held on 23 February 2017 at 15:00 CET IRVINE, CA, and HERSTAL, BELGIUM - February 9, 2017 - MDxHealth SA (Euronext: MDXH.BR) or the "Company" today announced that it will release its full year results for the financial year ended
Read more →MDXHMDxHealth Awarded US Department of Veterans Affairs Contract for ConfirmMDx Testing
NEWS RELEASE REGULATED INFORMATION INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - February 8, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that it has been awarded a US Government Services Administration (GSA) supply contract to use ConfirmMDx for Prostate Ca
Read more →MDXHMDxHealth Announces Horizon Blue Cross Blue Shield of New Jersey Issues Positive Coverage Policy on ConfirmMDx
NEWS RELEASE REGULATED INFORMATION INSIDE INFORMATION Decision provides access to more than 3.8 million members IRVINE, CA, and HERSTAL, BELGIUM - January 18, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that Ho
Read more →MDXHMDxHealth Announces Preliminary Update on 2016 Results and Appointment of CFO
On track to meet full-year earnings guidance based on strong ConfirmMDx growth Jean-Marc Roelandt appointed Chief Financial Officer IRVINE, CA, and HERSTAL, BELGIUM - January 9, 2017 - MDxHealth SA (Euronext: MDXH.BR) today provides a preliminary update on its year-end results,
Read more →MDXHMDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
PRESS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - December 19, 2016 - MDxHealth SA (Euronext: MDXH.BR) announced today that it has signed a distribution agreement with AceCGT Life Science Limited for their SelectMDx(TM) for Prostate C
Read more →MDXHMDxHealth Receives ISO 13485:2016 Certification for Dutch Laboratory
REGULATED INFORMATION Key step for MDxHealth's in vitro diagnostic (IVD) strategy in Europe Certification enables development, manufacturing and distribution of IVD products IRVINE, CA, and HERSTAL, BELGIUM, December 16, 2016 - MDxHealth SA (Euronext: MDXH), announces that its
Read more →MDXHMDxHealth to Present at November 2016 Investor Conferences
IRVINE, CA, and HERSTAL, BELGIUM - November 14, 2016 - MDxHealth SA (Euronext: MDXH.BR), today announced that Dr. Jan Groen, Chief Executive Officer, will present at the following investor conferences this month: 2016 Canaccord Genuity Medical Technology & Diagnostics Forum Dat
Read more →MDXHMDxHealth's AssureMDx Multi-Center Validation Study Published in the Journal of Urology
99% Negative Predictive Value could lead to 77% reduction in invasive cystoscopy procedures IRVINE, CA, and HERSTAL, BELGIUM, November 10, 2016 - MDxHealth SA (Euronext: MDXH), today announced that a second clinical validation study, demonstrating the performance of its urine-ba
Read more →MDXHMDxHealth Successfully Raises EUR 20.4 million (USD 22.6 million) In Equity Placement
THIS ANNOUCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURIDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW IRVINE, CA, and HERSTAL, BELGIUM - November 3, 2016 - MDxHealth
Read more →MDXHMDxHealth Launches Equity Placement
THIS ANNOUCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURIDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW IRVINE, CA, and HERSTAL, BELGIUM - November 2, 2016 - MDxHealth
Read more →MDXHMDxHealth Provides Third Quarter 2016 Business Update
Revenue for the first nine months up 84% to $22 million Continued strong growth attributed to increased payor coverage IRVINE, CA, and HERSTAL, BELGIUM - November 2, 2016 - MDxHealth SA (Euronext: MDXH.BR), today announced its third quarter 2016 Business Update for the period e
Read more →MDXHMDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
REGULATED INFORMATION MDxHealth An n ounces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association Current Procedural Terminology code will facilitate reimbursement IRVINE, CA, and HERSTAL, BELGIUM - October 31, 2016 - MDxHealth SA (Euronext: MDXH.BR), to
Read more →MDXHMDxHealth Announces Positive Coverage Policy with Fourth-Largest Health Insurer in the United States
Health Care Services Corporation Operates Blue Cross and Blue Shield® Plans in Illinois, Montana, New Mexico, Oklahoma and Texas IRVINE, CA, and HERSTAL, BELGIUM - October 27, 2016 - MDxHealth SA (Euronext: MDXH.BR) today announced that Health Care Services Corporation (HCSC) ha
Read more →MDXHMDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
Further broadens reach of SelectMDx(TM) for Prostate Cancer in Europe IRVINE, CA, and HERSTAL, BELGIUM - October 19, 2016 - MDxHealth SA (Euronext: MDXH.BR) a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatm
Read more →MDXHMDxHealth Reports Highmark Blue Cross Blue Shield Issues Positive Medical Policy on ConfirmMDx
Highmark BCBS serves 5.2 million members in Pennsylvania, Delaware & West Virginia IRVINE, CA, and HERSTAL, BELGIUM - October 6, 2016 - MDxHealth SA (Euronext: MDXH.BR) today announced that Highmark BCBS (Highmark) has issued a positive medical coverage policy decision for the C
Read more →MDXHMDxHealth Announces Agreement with SouthGenetics for Distribution of SelectMDx in Central/South America
IRVINE, Calif. and HERSTAL, Belgium, Oct. 4, 2016 (GLOBE NEWSWIRE) -- MDxHealth SA (Euronext: MDXH.BR) a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of urologic cancers, today announced that it has si
Read more →MDXHMDxHealth and The European Health Centre Innovation Sign Distribution Agreement for SelectMDx and ConfirmMDx in Poland
IRVINE, CA, and HERSTAL, BELGIUM - September 28, 2016 - MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a distribution agreement with The European Health Centre Innovation (EHC Innovation) to offer its SelectMDx(TM) for Prostate Cancer and ConfirmMDx® for Pro
Read more →MDXHMDxHealth Announces Independence Blue Cross Rendered Positive Medical Coverage Policy for ConfirmMDx
Independence serves 8.5 million people in 32 states plus Washington DC IRVINE, CA, and HERSTAL, BELGIUM - September 27, 2016 - MDxHealth SA (Euronext: MDXH.BR) announced that Independence Blue Cross (Independence) has issued a positive medical coverage policy decision for the Co
Read more →MDXHMDxHealth Announces Upgraded Revenue Forecast
Company expects to significantly exceed upper range of previous guidance Accelerated Growth attributed to increased payor coverage IRVINE, CA, and HERSTAL, BELGIUM - September 22, 2016 - MDxHealth SA (Euronext: MDXH.BR) announced today that its preliminary unaudited revenues ar
Read more →MDXHMDxHealth Gains Medi-Cal Approval for ConfirmMDx
Opens testing access to the largest state-run health plan in the United States IRVINE, CA, and HERSTAL, BELGIUM - September 6, 2016 - MDxHealth SA (Euronext: MDXH.BR) announced that the ConfirmMDx® for Prostate Cancer test is now available as an in-network benefit under the Cali
Read more →MDXHMDxHealth and Teva Pharmaceuticals Sign Distribution Agreement for SelectMDx in Israel
IRVINE, CA, and HERSTAL, BELGIUM - August 31st, 2016 - MDxHealth SA (Euronext: MDXH.BR), announced today that it has signed a distribution agreement with Teva Pharmaceuticals to offer its SelectMDx(TM) for Prostate Cancer test to Teva's urology customers throughout Israel. Under
Read more →MDXHMDxHealth Reports Second Quarter and First Half 2016 Results
Q2 ConfirmMDx revenues up 79%; total revenues up 63% Eight new and expanded ConfirmMDx® insurance agreements in Q2 Six new insurance agreements for SelectMDx in Q2 Mark Shaffar appointed as Chairman of the board IRVINE, CA, and HERSTAL, BELGIUM - August 18, 2016 - MDxHealth S
Read more →MDXHMDxHealth Announces Positive Medical Policy for ConfirmMDx Issued by One of the Top Five Health Insurers in the US
IRVINE, CA, and HERSTAL, BELGIUM - August 10, 2016 - MDxHealth SA (Euronext: MDXH.BR) announced a positive medical policy decision for ConfirmMDx® for Prostate Cancer test issued by Cigna, one of the top five largest health insurers in the US. This positive medical policy decisi
Read more →MDXHMDxHealth and Cerba HealthCare Announce Collaboration Agreement for SelectMDx Commercialization
Partnership increases patient access throughout France, Belgium and Luxembourg IRVINE, CA, and ZWIJNAARDE, BELGIUM - July 25th, 2016 - MDxHealth SA (Euronext: MDXH.BR) and Cerba HealthCare Belgium, announced today that they have signed a Collaboration Agreement to bring MDxHealt
Read more →MDXHmdxhealth investor newsletter june 2016
mdxhealth investor newsletter june 2016
Read more →MDXHMDxHealth Secures New Reimbursement Coverage for SelectMDx
Contract with Fortified Provider Network Covers 5 Million Lives IRVINE, CA, and HERSTAL, BELGIUM - June 28, 2016 - MDxHealth SA (Euronext: MDXH.BR), announced today that it has secured reimbursement coverage agreement for its SelectMDx(TM) for Prostate Cancer test with Fortified
Read more →MDXHMDxHealth Contracts with Priority Health for Coverage of ConfirmMDx
IRVINE, CA, and HERSTAL, BELGIUM - June 23, 2016 - MDxHealth SA (Euronext: MDXH.BR), announced that it has contracted with Priority Health, a Michigan-based health plan with nearly 720,000 members, for coverage of ConfirmMDx® for Prostate Cancer testing for its Commercial and Med
Read more →MDXHMDxHealth Announces Agreement with Major Academic Medical Center for ConfirmMDx Testing
IRVINE, CA, and HERSTAL, BELGIUM - June 21, 2016 - MDxHealth SA (Euronext: MDXH.BR), announced today that it has entered into an agreement with Duke University Health System regarding the use of its ConfirmMDx for Prostate Cancer test. The test is approved for the management of m
Read more →MDXHMDxHealth : Extraordinary General Shareholders' Meeting
IRVINE, CA, and HERSTAL, BELGIUM, 20 June 2016 -MDxHealth SA (NYSE Euronext: MDXH.BR), held its Extraordinary General Meeting of Shareholders in Diegem today. The shareholders approved all agenda items of the Extraordinary General Meeting of Shareholders. This press release cont
Read more →MDXHMDxHealth Announces European Urology Editorial Supporting SelectMDx Use in Detecting Prostate Cancer
IRVINE, CA, and HERSTAL, BELGIUM - June 16, 2016 - MDxHealth SA (Euronext: MDXH.BR), announced today the publication of an editorial in the prestigious journal European Urology that supports the integration of SelectMDx(TM) liquid biopsy test results into established clinical alg
Read more →MDXHMDxHealth (R): Grants QIAGEN Rights to MSP Technology for QIAsure Methylation Test for Cervical Cancer Risk
IRVINE, Calif. and HERSTAL, Belgium, June 15, 2016 (GLOBE NEWSWIRE) -- MDxHealth SA (Euronext: MDXH.BR), announced today that it has granted a non-exclusive worldwide license for its patented methylation-specific PCR (MSP) technology to QIAGEN for use in its new CE-marked QIAsure
Read more →MDXHMDxHealth Holds Capital Markets Day in New York City
Key Opinion Leaders Highlight MDxHealth's Commercial Portfolio IRVINE, CA, and HERSTAL, BELGIUM - June 14, 2016 - MDxHealth SA (Euronext: MDXH.BR), announced that a replay of its Capital Markets Day presentation, held earlier today in New York City, is currently available. Durin
Read more →MDXHMDxHealth Secures First Reimbursement Coverage for SelectMDx
IRVINE, CA, and HERSTAL, BELGIUM - June 14, 2016 - MDxHealth SA (Euronext: MDXH.BR), announced today that it has secured the first U.S. reimbursement coverage agreement for its SelectMDx(TM) for Prostate Cancer test with America's Choice Provider Network, Inc. (ACPN). ACPN is a
Read more →MDXHMDxHealth (R): Disclosure of the Number of Outstanding Voting Securities
IRVINE, CA and HERSTAL, BELGIUM, May 20, 2016 - MDxHealth SA (NYSE Euronext: MDXH) ("MDxHealth") announced today, pursuant to Article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulate
Read more →MDXHMDxHealth's ConfirmMDx Stratifies Risk for Aggressive Prostate Cancer
Multicenter validation study published in the journal The Prostate IRVINE, CA, and HERSTAL, BELGIUM - May 9, 2016 - MDxHealth SA (Euronext: MDXH.BR) announced today the publication of multicenter validation data demonstrating that ConfirmMDx® for Prostate Cancer can aid in the i
Read more →MDXHMDxHealth Announces Positive Data Supporting Prognostic Value of ConfirmMDx and SelectMDx for Prostate Cancer
Data are Presented at the American Urological Association Annual Meeting, 6-10 May 2016, San Diego IRVINE, CA, and HERSTAL, BELGIUM - 06 May, 2016 - MDxHealth SA (Euronext: MDXH.BR) is presenting positive data demonstrating the prognostic value of its SelectMDx® and ConfirmMDx®
Read more →MDXHMDxHealth Provides First Quarter 2016 Business Update
Revenue Increased 66% Over First Quarter 2015 IRVINE, CA, and HERSTAL, BELGIUM - May 3, 2016 - MDxHealth SA (Euronext: MDXH.BR) today issued its business update for the quarter ended March 31, 2016. "ConfirmMDx sales increased sharply during the first quarter of 2016, over the
Read more →MDXHMDxHealth's SelectMDx Study Published in European Urology
Data validates 'liquid biopsy' test's ability to identify men at risk for aggressive cancer IRVINE, CA, and HERSTAL, BELGIUM - April 25, 2016 - MDxHealth SA (Euronext: MDXH.BR), today announced that data validating the clinical performance of the SelectMDx(TM) for Prostate Cance
Read more →MDXHMDxHealth Partners with Andros Men's Clinic to Offer SelectMDx for Prostate Cancer
IRVINE, CA, and HERSTAL, BELGIUM - March 29, 2016 - MDxHealth SA (Euronext: MDXH.BR), announced today that it has partnered with Andros Men's Health Clinic (Andros Mannenkliniek) in The Netherlands to offer the SelectMDx(TM) for Prostate Cancer test to their patients. Through th
Read more →MDXHMDxHealth Launches SelectMDx "Liquid Biopsy" Test in the United States
Non-invasive, urine-based prostate cancer assay available as a laboratory developed test IRVINE, CA, and HERSTAL, BELGIUM - March 17, 2016 - MDxHealth SA (Euronext: MDXH.BR), today announced the commercial launch of its SelectMDx(TM) for Prostate Cancer test in the United States
Read more →MDXHMDxHealth Presents SelectMDx(TM) Results from Multicenter Validation Study at the 2016 Annual EAU Congress
SelectMDx awarded best poster presentation by EAU's Scientific Congress Office IRVINE, CA, and HERSTAL, BELGIUM - March 14, 2016 - MDxHealth SA (Euronext: MDXH.BR), announced today that positive results of a prospective, multicenter validation study of SelectMDx(TM) for Prostate
Read more →MDXHMDxHealth Appoints Global Commercial Team for SelectMDx
IRVINE, CA, and HERSTAL, BELGIUM - March 9, 2016 - MDxHealth SA (Euronext: MDXH.BR) announced today that it has appointed a global commercial team to drive the launch of the Company's new non-invasive, urine-based test, SelectMDx(TM) for Prostate Cancer. MDxHealth is employing a
Read more →MDXHMDxHealth Announces Inclusion of ConfirmMDx in 2016 NCCN Guidelines for Prostate Cancer Early Detection
IRVINE, CA, and HERSTAL, BELGIUM - March 2, 2016 - MDxHealth SA (Euronext: MDXH.BR), today announced that its ConfirmMDx® for Prostate Cancer test has been included in the United States' 2016 National Comprehensive Cancer Network (NCCN) Guidelines. The NCCN is an alliance of 23 w
Read more →MDXHMDxHealth Reports Fourth Quarter and Fiscal Year 2015 Results
Full Year ConfirmMDx Revenue up 62% Compared to Full Year 2014 IRVINE, CA, and HERSTAL, BELGIUM - 7:00 AM, February 18, 2016 - MDxHealth SA (Euronext: MDXH.BR) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2015. Financial Highli
Read more →MDXHMDxHealth Announces Conference Participation for First Half 2016
IRVINE, CA, and HERSTAL, BELGIUM - January 28, 2016 - MDxHealth SA (Euronext: MDXH.BR), announced today that it will be participating at the following key conferences during the first half of 2016: Bank Degroof Petercam Healthcare CEO Seminar on 03 February, Hotel Bloom Brussels
Read more →MDXHMDxHealth Receives 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award
IRVINE, CA, and HERSTAL, BELGIUM - January 21, 2016 - MDxHealth SA (Euronext: MDXH.BR) announced today that it received the 2016 Frost & Sullivan Global Technology Innovation Award for its commitment to technological innovation to reduce unnecessary prostate biopsies. Frost & Su
Read more →MDXHMDxHealth Analytical Validation Study on AssureMDx for Bladder Cancer Published in The Journal of Urology
Liquid Biopsy Test Delivers High Negative Predictive Value of 99.2% for Bladder Cancer IRVINE, CA, and HERSTAL, BELGIUM, January 19, 2016 - MDxHealth SA (Euronext: MDXH), today announced that data demonstrating the clinical potential of its urine-based epigenetic bladder cancer
Read more →MDXHMDxHealth Provides Preliminary Update on 2015 Results, Reporting Strong Sales Trajectory for ConfirmMDx
IRVINE, CA, and HERSTAL, BELGIUM - January 12, 2016 - MDxHealth SA (Euronext: MDXH.BR), today provides a preliminary update on its year-end results, reporting that it has met its market guidance for 2015 (projected annual revenues of $16-20 million and case volumes of 15,000 to 1
Read more →MDXHMDxHealth Announces Positive Data Supporting Expanded Diagnostic Application for ConfirmMDx for Prostate Cancer
Data Presented at the Annual Genitourinary Cancers Symposium in San Francisco, January 7-9 2016 IRVINE, CA, and HERSTAL, BELGIUM - January 11, 2016 - MDxHealth SA (Euronext: MDXH.BR) announced positive data today from two abstracts demonstrating the prognostic value of its Conf
Read more →MDXHMDxHealth Announces ConfirmMDx Marketing Partnership in Central/South America
IRVINE, CA, and HERSTAL, BELGIUM - December 8, 2015 - MDxHealth SA (Euronext: MDXH.BR), announced today that it has partnered with SouthGenetics Inc. for the commercialization of its ConfirmMDx® for Prostate Cancer test in twelve countries across Central and South America. With
Read more →MDXHMDxHealth (R): Disclosure of the number of outstanding voting securities
IRVINE, CA, and HERSTAL, BELGIUM, 27 November, 2015 - MDxHealth SA (NYSE Euronext: MDXH), announced today, pursuant to article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated marke
Read more →MDXHMDxHealth to Participate in Prospective Clinical Validation Study with AssureMDx for Bladder Cancer
Study to Evaluate Ability to Reduce Invasive Procedures for Bladder Cancer Survivors and Allow Earlier Detection of Recurrence IRVINE, CA, and HERSTAL, BELGIUM, November XX, 2015 - MDxHealth SA (Euronext: MDXH), announced today that it has entered into an agreement with Erasmus
Read more →MDXHMDxHealth to Present at November 2015 Investor Conferences
IRVINE, CA, and HERSTAL, BELGIUM - November 4, 2015 - MDxHealth SA (Euronext: MDXH.BR), today announced that Dr. Jan Groen, Chief Executive Officer, will present at the following investor conferences this month: 4th KBC Securities Benelux Biotech & Healthcare Seminar Date: Tues
Read more →MDXHMDxHealth Provides Third Quarter 2015 Business Update
Revenue for the first nine months up 44% to $11.9 million 67% increase in case volume from previous quarter and 30% year-on-year growth Expansion of uro-oncology product offering and global commercial strategy IRVINE, CA, and HERSTAL, BELGIUM - November 3, 2015 - MDxHealth SA
Read more →MDXHMDxHealth to Participate in Prospective 4M Clinical Study Evaluating Synergy of MRI and SelectMDx for Prostate Cancer
600 Patient Study to Evaluate Emerging Technologies for Improved Selection of Patients for Prostate Biopsy IRVINE, CA, and HERSTAL, BELGIUM, October 19, 2015 - MDxHealth SA (Euronext: MDXH), has entered into an agreement with Radboud University Medical Center in Nijmegen, The Ne
Read more →MDXHMDxHealth Launches SelectMDx "Liquid Biopsy" Test in Europe
Non-invasive, urine-based prostate cancer test available in the Netherlands from November 2015 IRVINE, CA, and HERSTAL, BELGIUM - October 13, 2015 - MDxHealth SA (Euronext: MDXH.BR), announced today, the commercial launch of the Company's new non-invasive, urine-based test, Sele
Read more →MDXHMDxHealth Appoints Walter Narajowski as Independent Director
IRVINE, CA, and HERSTAL, BELGIUM - October 5, 2015 - MDxHealth SA (Euronext: MDXH.BR), today announces that it has strengthened its Board of Directors with the appointment of Mr. Walter Narajowski, a medical diagnostics business leader with over 25 years of industry experience.
Read more →MDXHMDxHealth(R): Completion of the acquisition of NovioGendix - New share capital amount and new number of shares
IRVINE, Calif. and HERSTAL, Belgium, Sept. 18, 2015 (GLOBE NEWSWIRE) -- MDxHealth SA (Euronext Brussels: MDXH) (the "Company") announced today that it succesfully completed the acquisition of all of the shares in NovioGendix Holding B.V. ("NovioGendix"). The acquisition of NovioG
Read more →MDXHMDxHealth's ConfirmMDx Covered by Tufts Health Plan
IRVINE, CA, and HERSTAL, BELGIUM - September 17, 2015 - MDxHealth SA (Euronext: MDXH.BR) announced that it has signed an agreement with Tufts Health Plan for their government and commercial programs/products. The agreement provides access to ConfirmMDx for Prostate Cancer testing
Read more →MDXHMDxHealth Acquires NovioGendix to Expand Uro-Oncology Product Offering
The acquisition gives MDxHealth access to a validated, non-invasive liquid biopsy test for prostate cancer in the US and EU Urine based test shown to be clinically superior to PCA3 prostate cancer test $8.8 million total acquisition cost, including $5.1 million in MDxHealth sto
Read more →MDXHMDxHealth Reports New ConfirmMDx Risk Score Data at 11th World Congress on Urological Research
Results demonstrate that patients can be stratified for low and high grade prostate cancer IRVINE, CA, and HERSTAL, BELGIUM, September 10, 2015 - MDxHealth SA (Euronext: MDXH), today announced data demonstrating that a newly developed algorithm, based on ConfirmMDx test scores
Read more →MDXHMDxHealth Reports First Half 2015 Results
Revenues up 64% to $7.9 million ConfirmMDx revenue up 77% to $6.9 million Cash position strengthened with $31.0 million private placement enabling greater expansion of sales force and pipeline expansion in H2 IRVINE, CA, and HERSTAL, BELGIUM - August 20, 2015 - MDxHealth SA (E
Read more →MDXHMDxHealth Announces Positive Top-Line Data for its Liquid Biopsy Test for Bladder Cancer
Signs worldwide exclusive agreement with Erasmus MC for bladder cancer DNA methylation markers Full data to be presented at 11th World Congress on Urological Research IRVINE, CA, and HERSTAL, BELGIUM, August 18, 2015 - MDxHealth SA (Euronext: MDXH), announced today positive top
Read more →MDXHMDxHealth Appoints Philip J. Ginsburg M.D. as Chief Medical Officer
IRVINE, CA, and HERSTAL, BELGIUM, June 14, 2015 - MDxHealth SA (Euronext: MDXH), announced today, the appointment of Philip J. Ginsburg, MD, as Chief Medical Officer (CMO). Dr. Ginsburg joins the company with over 20 years of commercial medical laboratory and urology experience.
Read more →MDXHMDxHealth - Transparency declaration update
IRVINE, CA, and HERSTAL, BELGIUM, July 9, 2015 - MDxHealth SA (Euronext: MDXH) (the "Company") announces, in accordance with article 14 of the Belgian Act of May 2, 2007 on the disclosure of significant shareholdings in listed companies, that it received shareholder notifications
Read more →MDXHMDxHealth's new share capital amount and new number of shares
IRVINE, CA, and HERSTAL, BELGIUM - June 26, 2015 - MDxHealth SA (Euronext Brussels: MDXH) announced today, in conformity with article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulate
Read more →MDXHMDxHealth Successfully Raises € 27.7 million (USD 31.0 million) In Equity Placement
THIS ANNOUNCEMENT IS NOT FOR Distribution, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, South Africa OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE prohibited by applicable law IRVINE, CA, and HERSTAL, BELGIUM - June 24, 2015 - MDxHealth
Read more →MDXHMDxHealth - Disclosure of the number of outstanding voting securities
IRVINE, CA, and HERSTAL, BELGIUM, June 8, 2015 - MDxHealth SA (Euronext: MDXH), announced today, pursuant to article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market, that on
Read more →MDXHMDxHealth - Annual General Shareholders' Meeting
IRVINE, CA, and HERSTAL, BELGIUM, May 29, 2015 -MDxHealth SA (Euronext: MDXH), held its Annual General Meeting of shareholders in Zaventem today. The shareholders approved all agenda items of the Annual General Meeting, including the financial statements for the financial year en
Read more →MDXHMDxHealth's ConfirmMDx(r) Predicts Prostate Cancer Aggressiveness
IRVINE, Calif. and HERSTAL, Belgium, May 18, 2015 (GLOBE NEWSWIRE) -- Epigenetic Health Index Helps Urologists with Prognostic Recommendations Data Supporting Expanded Application of ConfirmMDx Presented at the AUA 2015 MDxHealth SA (Euronext: MDXH.BR) revealed data today demon
Read more →MDXHMDxHealth's ConfirmMDx Predicts Prostate Cancer Aggressiveness
Epigenetic Health Index Helps Urologists with Prognostic Recommendations Data Supporting Expanded Application of ConfirmMDx Presented at the AUA 2015 IRVINE, CA, and HERSTAL, BELGIUM - May 18, 2015 - MDxHealth SA (Euronext: MDXH.BR) revealed data today demonstrating the prognos
Read more →MDXHMDxHealth Provides First Quarter 2015 Business Update
ConfirmMDx Test Revenue Increases 177% over First Quarter 2014 IRVINE, CA, and HERSTAL, BELGIUM - May 5, 2015 - MDxHealth SA (Euronext: MDXH.BR) today issued its business update for the quarter ended March 31, 2015. "Q1 2015 ConfirmMDx® for Prostate Cancer revenue more than dou
Read more →MDXHMDxHealth Named Winner of Corporate LiveWire Innovation & Excellence 2015 Award
IRVINE, CA, and HERSTAL, BELGIUM - April 24, 2015 - MDxHealth SA (Euronext: MDXH.BR) announced today that it has been named as one of the winners of the Corporate LiveWire Innovation & Excellence Awards. The awards are in recognition of innovation and excellence that recipient co
Read more →MDXHMDxHealth Completes Enrollment of Second ConfirmMDx Clinical Utility Study
PASCUAL Study Expected to Support Expanded Reimbursement IRVINE, CA, and HERSTAL, BELGIUM - April 20, 2015 - MDxHealth SA (Euronext: MDXH.BR) today announced that it has completed patient enrollment into its prospective, randomized PASCUAL clinical utility study with ConfirmMDx®
Read more →MDXHMDxHealth's ConfirmMDx Genes Detect Clinically Significant Prostate Cancer
Data Supporting Expanded Prognostic Application of Epigenetic Test Presented at the ASCO Genitourinary Cancers Symposium 2015 IRVINE, CA, and HERSTAL, BELGIUM - March 2, 2015 - MDxHealth SA (Euronext: MDXH.BR), today announced that data demonstrating the prognostic value of its
Read more →MDXHMDxHealth Reports Fourth Quarter and Fiscal Year 2014 Results
ConfirmMDx Full Year Revenue and Case Volume Continue Excellent Growth Trends IRVINE, CA, and HERSTAL, BELGIUM - 8:00 AM, February 26, 2015 - MDxHealth SA (Euronext: MDXH.BR), today announced results for the fourth quarter and the fiscal year ended December 31, 2014. ConfirmMDx
Read more →MDXHMDxHealth Named Euronext Best BEL Small Company Performer for 2014
IRVINE, CA, and HERSTAL, BELGIUM - January 21 2015 - MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that Euronext granted the 2014 B
Read more →MDXHMDxHealth Licenses Epigenetic Technology to oncgnostics GmbH for Cervical Cancer Test
IRVINE, CA, and HERSTAL, BELGIUM - January 14, 2015 - MDxHealth SA (Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has granted a limited worldwide license for its patented methylation specific PCR (M
Read more →MDXHMDxHealth CEO Dr Jan Groen to Deliver Keynote Presentation at Biomarkers from Research to Clinic Conference
IRVINE, CA, and HERSTAL, BELGIUM, January 5, 2015 - 8:00 AM CET - MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced today that its CEO, Dr Ja
Read more →MDXHMDxHealth to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
IRVINE, California, and HERSTAL, BELGIUM - November 12, 2014 - MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that CEO, Dr. Jan Groe
Read more →MDXHMDxHealth Successfully Raises € 12.33 million (US$ 15.43 million) In Equity Offering
THIS ANNOUNCEMENT IS NOT FOR Distribution, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, South Africa OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE prohibited by applicable law IRVINE, CA, and HERSTAL, BELGIUM - November 5, 2014 - MDxHeal
Read more →MDXHMDxHealth Provides Third Quarter 2014 Business Update
ConfirmMDx® for Prostate Cancer Revenue and Case Volume Continue Rapid Growth IRVINE, CA, and HERSTAL, BELGIUM, November 4, 2014 - MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and
Read more →MDXHMDxHealth's ConfirmMDx Genes Identify Prostate Cancer Aggressiveness in Diagnostic Biopsies
Data Presented at the 2014 European Association of Urology Meeting IRVINE, CA, and HERSTAL, BELGIUM - October 10, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and trea
Read more →MDXHMDxHealth Presents Results from Epigenetic Test to Identify Prostate Cancer Aggressiveness at the European Association of Urology Meeting 2014
IRVINE, CA, and HERSTAL, BELGIUM - October 7, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will prese
Read more →MDXHMDxHealth's ConfirmMDx for Prostate Cancer Test Qualifies for Medicare Coverage Effective November 3, 2014
Company initiates enrollment into prospective PASCUAL clinical utility trial IRVINE, California, and HERSTAL, BELGIUM - September 23, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve th
Read more →MDXHMDxHealth to Participate in the Rodman & Renshaw 16th Annual Global Investment Conference
IRVINE, California, and HERSTAL, BELGIUM - September 8, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company
Read more →MDXHMDxHealth Reports First Half Year 2014 Results
Strong market adoption leads to more than doubling of ConfirmMDx case volume IRVINE, CA, and HERSTAL, BELGIUM - August 21, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis
Read more →MDXHMDxHealth ConfirmMDx Biomarker Associated with the Risk of Recurrence for Early Stage Prostate Cancer Patients
Validation Study Data Published in The Journal of Urology® IRVINE, California, and HERSTAL, BELGIUM - August 18, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treat
Read more →MDXHMDxHealth Signs Two New Insurance Agreements Providing Increased Access to ConfirmMDx for Prostate Cancer
Agreements add more than 4.5 million insured lives IRVINE, CA, and HERSTAL, BELGIUM - August 14, 2014 MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer pat
Read more →MDXHMDxHealth (R) : MDxHealth Licensee Exact Sciences Receives FDA Approval for its Cologuard Colon Cancer Screening Assay
IRVINE, Calif. , and HERSTAL, Belgium, Aug. 12, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that th
Read more →MDXHMDxHealth and Miraca Life Sciences Announce Agreement to Promote ConfirmMDx for Prostate Cancer
IRVINE, CA, and HERSTAL, BELGIUM - July 2, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has entered into an ag
Read more →MDXHMDxHealth's Annual and Extraordinary General Shareholders' Meeting
IRVINE, CA, and HERSTAL, BELGIUM, 30 May, 2014 -MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, held its Annual and Extraordinary General Meeting of shareholders in Zaventem
Read more →MDXHMDxHealth Reports 10-Fold Reduction of Repeat Prostate Biopsies in ConfirmMDx Clinical Utility Study
Results Published in American Health and Drug Benefits IRVINE, CA, and HERSTAL, BELGIUM - May 20, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer
Read more →MDXHMDxHealth Announces Presentations on ConfirmMDx for Prostate Cancer at American Urological Association 2014 Annual Meeting
IRVINE, CA, and HERSTAL, BELGIUM - May 15, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that results from its pivotal
Read more →MDXHMDxHealth and American Pathology Partners Announce Marketing Agreement for ConfirmMDx for Prostate Cancer
IRVINE, CA, and LIEGE, BELGIUM - May 13, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has entered into a co-ma
Read more →MDXHMDxHealth's ConfirmMDx DOCUMENT Validation Study Published in the Journal of Urology
ConfirmMDx is Most Significant Independent Predictor for Prostate Cancer in a Repeat Biopsy IRVINE, CA, and HERSTAL, BELGIUM - May 8, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve th
Read more →MDXHMDxHealth Provides First Quarter 2014 Business Update
ConfirmMDx Test Volume Increases 257% over First Quarter 2013 IRVINE, CA, and HERSTAL, BELGIUM - May 6, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of c
Read more →MDXHMDxHealth Signs Agreement with Galaxy Health Network PPO Providing Increased Access to ConfirmMDx for Prostate Cancer
Agreement Increases Access with Additional 3.5 Million Covered Lives IRVINE, Calif. and HERSTAL, Belgium, April 22, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve th
Read more →MDXHMDxHealth and LI PATH Announce Marketing Agreement for ConfirmMDx for Prostate Cancer
IRVINE, Calif. and HERSTAL, Belgium, April 2, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it h
Read more →MDXHMDxHealth Licensee Exact Sciences Receives FDA Panel Recommendation for Approval of Colorectal Cancer Screening Test
MDxHealth's Epigenetic Biomarker Used in Cologuard Test IRVINE, CA, and HERSTAL, BELGIUM - March 28, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of canc
Read more →MDXHMDxHealth's PredictMDx for Glioblastoma Identifies Newly Diagnosed Patients with Improved Progression Free and Overall Survival
Results of Phase III Trial for Bevacizumab (Avastin®) Published in the New England Journal of Medicine IRVINE, California, and HERSTAL, BELGIUM - March 4, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenet
Read more →MDXHMDxHealth Reports Fourth Quarter and Fiscal Year 2013 Results
IRVINE, Calif. and HERSTAL, Belgium, Feb. 27, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results f
Read more →MDXHMDxHealth Secures Agreement with Prime Health Services PPO Network Providing Increased Access to ConfirmMDx for Prostate Cancer
Agreement Increases Access with Additional 6 Million Covered Lives IRVINE, CA, and HERSTAL, BELGIUM -- 8:00 AM, February 20, 2014 MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis
Read more →MDXHMDxHealth's ConfirmMDx(R) for Prostate Cancer Epigenetic Test Correctly Identifies Prostate Cancer Missed in Five Previous Biopsies
IRVINE, Calif. and HERSTAL, Belgium, Feb. 12, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the
Read more →MDXHMDxHealth's ConfirmMDx for Prostate Cancer Epigenetic Test Correctly Identifies Prostate Cancer Missed in Five Previous Biopsies
Multidisciplinary Case Study Published in The Journal of OncoPathology IRVINE, CA, and HERSTAL, BELGIUM -- 8:00 AM, February 12, 2014 MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagn
Read more →MDXHMDxHealth's ConfirmMDx Genes Identify Aggressive Prostate Cancer
Data Presented at the 2014 ASCO Genitourinary Cancers Symposium IRVINE, CA, and HERSTAL, BELGIUM - February 3, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatme
Read more →MDXHMDxHealth to Present Results from Epigenetic Prostate Test to Identify Aggressive Prostate Cancer at the ASCO Genitourinary Cancers Symposium 2014
IRVINE, Calif. and HERSTAL, Belgium, Jan. 29, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the
Read more →MDXHMDxHealth Announces Agreement with Teva Pharmaceuticals for Commercialization of Two Cancer Tests in Israel
ConfirmMDx for Prostate Cancer and PredictMDx for Glioblastoma Made Available Through Teva's Extensive Oncology Network IRVINE, CA, and HERSTAL, BELGIUM - 8:00 AM, January 23, 2014 MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and comme
Read more →MDXHMDxHealth Secures Coverage for Prostate Cancer Test with Two Additional Insurance Companies
IRVINE, CA, and HERSTAL, BELGIUM -- 8:00 AM, December 2, 2013 MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed
Read more →MDXHMDxHealth Provides Third Quarter 2013 Business Update
Commercial Revenues Increase 132% over Q3 2012 IRVINE, CA, and HERSTAL, BELGIUM, November 6, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patie
Read more →MDXHMDxHealth's MGMT Test Included in NCCN Guidelines and Awarded Tier 1 Reimbursement Code by AMA
IRVINE, Calif. and HERSTAL, Belgium, Oct. 16, 2013 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext:MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the c
Read more →MDXHMDxHealth's ConfirmMDx(R) Meets All Primary Endpoints in Blinded U.S. Clinical Validation Study
IRVINE, Calif. and HERSTAL, Belgium, Oct. 7, 2013 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext:MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that its Co
Read more →MDXHMDxHealth's ConfirmMDx Meets All Primary Endpoints in Blinded U.S. Clinical Validation Study
IRVINE, CA, and HERSTAL, BELGIUM - 8:00 AM, October 7, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that its ConfirmMD
Read more →MDXHMDxHealth Insurance Agreements Expand Access to ConfirmMDx(R) for Prostate Cancer Test
IRVINE, Calif. and HERSTAL, Belgium, Oct. 1, 2013 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext:MDXH), a leading molecular diagnostics company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it ha
Read more →MDXHMDxHealth Signs Agreement with Stratose to Expand Insurance Coverage for ConfirmMDxTM for Prostate Cancer Test
IRVINE, CA, and HERSTAL, BELGIUM -- September 3, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, today announced that it has entered into
Read more →MDXHMDxHealth Reports 2013 First-Half Results
Over 80% Increase in ConfirmMDxTM for Prostate Cancer Test Volume From Q1 to Q2 2013 IRVINE, CA, and LIEGE, BELGIUM, August 22, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diag
Read more →MDXHMDxHealth Establishes Agreements with MultiPlan and Three Rivers Provider Network for ConfirmMDxTM for Prostate Cancer
New Managed Care Network Agreements Add 67 Million Covered Lives IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM, July 30, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and tr
Read more →MDXHMDxHealth and Bostwick Laboratories Announce Marketing Agreement for ConfirmMDx(TM) for Prostate Cancer
IRVINE, CA, UNIONDALE, NY and LIEGE, BELGIUM - 8:00 AM CET, July 29, 2013 - MDxHealth SA (NYSE Euronext: MDXH) and Bostwick Laboratories, Inc. today announced that they have entered into a marketing agreement to commercialize MDxHealth's ConfirmMDx for Prostate Cancer test. Bost
Read more →MDXHMDxHealth Collaborates with HistoGeneX to offer Pharmaco Molecular Diagnostic Services
IRVINE, CA, LIEGE and ANTWERP, BELGIUM - 8:00 AM CET, July 16, 2013 - MDxHealth SA (NYSE Euronext: MDXH) and HistoGeneX N.V. today announced the commencement of a Pharmaco Molecular Diagnostic services collaboration. The collaboration enables MDxHealth to combine its epigenetic t
Read more →MDXHMDxHealth's Prostate Cancer Test Approved by New York State Department of Health
IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM, July 10, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, today announced that the New York Stat
Read more →MDXHMDxHealth Shareholder Transparency Notifications
Regulated information IRVINE, CA, and LIEGE, BELGIUM, July 9, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, announced today that it re
Read more →MDXHMDxHealth's new share capital amount and number of shares
LIEGE, BELGIUM - July 2, 2013 - MDxHealth SA (NYSE Euronext : MDXH), in conformity with article 15 of the Law of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market, and further to the capital increase
Read more →MDXHMDxHealth and Sumitomo Sign Pharmaco Molecular Diagnostic Partnership for Japan
IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM, July 1, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, today announced the signing of a partne
Read more →MDXHMDxHealth Extraordinary General Shareholders' Meeting
IRVINE, CA, and LIEGE, BELGIUM, 27 June 2013 -MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, held its Extraordinary General Meeting of shareholders in Zaventem today. The sh
Read more →MDXHMDxHealth Completes €18 Million ($24M) Equity Raise
LIEGE, BELGIUM - June 25, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, announced today that it successfully raised an aggregate amoun
Read more →MDXHMDxHealth Announces Changes to its Board of Directors
Dr. Rudi Pauwels, PhD, Biocartis Chairman and CEO, Elected as new Independent Director IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM, June 18, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to suppor
Read more →MDXHMDxHealth Epigenetic Marker as Companion Diagnostic for Irinotecan based Therapy in Colorectal Cancer
Data Presented at ASCO IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM, June 3, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced data showing that methylation
Read more →MDXHMDxHealth (TM) : Annual and Extraordinary General Shareholders' Meeting
IRVINE, CA, and LIEGE, BELGIUM, 31 May, 2013 -MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, held its Annual and Extraordinary General Meeting of shareholders in Zaventem to
Read more →MDXHMDxHealth's ConfirmMDx(TM) Combined with PSA and Other Risk Factors, Improves Diagnosis of Prostate Cancer
ConfirmMDx Highlighted in Presentation on New Biomarker Algorithm for Prostate Cancer at 2013 AUA Conference IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM, May 8, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigen
Read more →MDXHMDxHealth Provides First Quarter 2013 Business Update
Revenue increases 51% over first quarter 2012 IRVINE, CA, and LIEGE, BELGIUM - May 7, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today issued its business update
Read more →MDXHMDxHealth's ConfirmMDx(TM) Test Outperforms PSA in Prostate Cancer Detection Algorithm and Decision for Repeat Biopsy
Presentations at 2013 American Urology Association Annual Meeting Discuss How ConfirmMDx for Prostate Cancer and Detection Algorithm Helps Men Avoid Unnecessary Repeat Prostate Biopsies and Aid Urologists to Improve Patient Management IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM,
Read more →MDXHMDxHealth Announces Publication of the Clinical Utility of Combining Genetics and Epigenetics to Improve Management of Prostate cancer
IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM, April 3, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced the publication of the clinical utility of epigeneti
Read more →MDXHMDxHealth Receives ISO 9001:2008 Certification for its Commercial U.S. Based CLIA Laboratory
IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM, April 2, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced that its Irvine, CA based CLIA certified and College
Read more →MDXHMDxHealth and Ghent University Aim to Establish Sensitive and Cost-Effective Industry Standard for Genome-wide DNA methylation Profiling Tools
Data from Epigenetic Sequencing Study Published in PLOS One IRVINE, CA, and LIEGE, BELGIUM - March 19, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of ca
Read more →MDXHMDxHealth Reports Fourth Quarter and Fiscal Year 2012 Results
Regulated Information Revenue of €4.6M ($6.0M), an increase of 71% versus fiscal year 2011 IRVINE, CA, and LIEGE, BELGIUM - 8:00 AM, February 28, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests
Read more →MDXHMDxHealth Announces Results from the ConfirmMDx(TM) for Prostate Cancer Test Studies Presented at the 2013 ASCO Genitourinary Cancers Symposium
IRVINE, CA, and LIEGE, BELGIUM - February 18, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, today announced the results of two studies
Read more →MDXHMDxHealth Announces Publication of Health Economic Analysis Demonstrating Cost-Savings of ConfirmMDx for Prostate Cancer
Budget Impact Model: Epigenetic Assay Can Help Avoid Unnecessary Repeated Prostate Biopsies and Reduce Healthcare Spending IRVINE, CA, and LIEGE, BELGIUM - February 14, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercial
Read more →MDXHMDxHealth Announces Presentations on the ConfirmMDx(TM) for Prostate Cancer Test at the ASCO Genitourinary Cancers Symposium 2013
IRVINE, CA, and LIEGE, BELGIUM - February 13, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, today announced that the company will prese
Read more →MDXHMDxHealth Announces Publication of Positive Data from a Blinded Multicenter Clinical Study Demonstrating the Utility of ConfirmMDxTM for Prostate Cancer to Address False-negative Biopsies
Results of the Study Published in the Journal of Urology IRVINE, CA, and LIEGE, BELGIUM - February 11, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of ca
Read more →MDXHMDxHealth to Present at the 2013 BIO CEO & Investor Conference
IRVINE, CA, and LIEGE, BELGIUM - February 4, 2013 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer diagnosis and treatment, today announced that Dr. Jan Groen , the Company's Chief Ex
Read more →MDXHMDxHealth announces its delisting from Euronext Amsterdam
IRVINE, CA, and LIEGE, BELGIUM, 29 November 2012 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, currently listed on Euronext Brussels and Euronext Amsterdam, announced tod
Read more →MDXHMDxHealth Provides Third Quarter 2012 Business Update
IRVINE, CA, and LIEGE, BELGIUM, November 15, 2012 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today published a business update for the third quarter ending September 3
Read more →MDXHMDxHealth is continually improving their subscribers experience
In order to continue receiving MDxHealth's press releases or other Company information, please click on the link below to select the type and language of the press releases offered. www.mdxhealth.com then press the 'subscribe' link at the top right of the page. We thank you in
Read more →MDXHMDxHealth Reports 2011 Half-Year Results
IRVINE, CA, and LIEGE, BELGIUM - August 25, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, announced today its 2011 half-year results. New companion diagnostics partnership with Pfizer Extended companion
Read more →MDXHMDxHealth establishes US CLIA laboratory in Irvine, CA, and makes key hires to expand US team
DURHAM, NC, and LIEGE, BELGIUM - August 18, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, announced today that it has signed a lease agreement for a state-of-the-art laboratory and office facilities in Ir
Read more →MDXHMDxHealth's biomarker part of large pivotal colon cancer trial initiated by Exact Sciences
DURHAM, NC, and LIEGE, BELGIUM - August 3, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, announced today that its licensing partner Exact Sciences Corp. (Nasdaq: EXAS) has initiated a large pivotal trial
Read more →MDXHMDxHealth's MGMT Test Shown to Be Only Prognostic Factor in Journal of Clinical Oncology Report on Newly Diagnosed Brain Cancer Patients
DURHAM, NC, and LIEGE, BELGIUM - July 11, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its MGMT test (PredictMDx(TM) for Brain) was shown to be the only prognostic factor for
Read more →MDXHMDxHealth and Merck KGaA extend Agreement for use of MGMT Assay in Brain Cancer Clinical Trials
DURHAM, NC, and LIEGE, BELGIUM - June 9th, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT
Read more →MDXHMDxHealth's MGMT Test Identifies Brain Cancer Patients Likely to Live Longer on Temozolomide Treatment - Phase III Data Presented at ASCO
DURHAM, NC, and LIEGE, BELGIUM - June 6, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its MGMT test (PredictMDxTM for Brain) was shown to successfully identify those recently
Read more →MDXHMDxHealth's Methylation Based Companion Diagnostics Enables Better Personalized Treatment in Brain Cancer
Data to be Presented at ASCO from RTOG 0525 International Phase III Trial of Temozolomide DURHAM, NC, and LIEGE, BELGIUM - May 31, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced th
Read more →MDXHMDxHealth Provides First Quarter 2011 Business Update
DURHAM, NC, and LIEGE, BELGIUM - May 18, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the quarter ended March 31, 2011. Continued Year-on-Year improvement of key fin
Read more →MDXHMDxHealth's Methylation Tests Detect Prostate Cancer in Patients Deemed Low Risk by Pathology
Results of Collaboration with Beth Israel Deaconess Medical Center, Harvard Medical School, New England Baptist Hospital Presented at American Urology Association Annual Meeting DURHAM, NC, and LIEGE, BELGIUM - May 16, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecul
Read more →MDXHMDxHealth Receives USD 1.1 Million European Grant to Progress Bladder Cancer Program
DURHAM, NC, and LIEGE, BELGIUM - May 3, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that together with partner NovioGendix B.V., a molecular diagnostics company spun out from Rad
Read more →MDXHMDxHealth Successfully Raises € 8.2 Million In Equity Issue
DURHAM, NC, and LIEGE, BELGIUM - April 5, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has successfully raised approximately € 8.2 million in gross proceeds through a priv
Read more →MDXHMDxHealth Launches Equity Offering
DURHAM, NC, and LIEGE, BELGIUM - April 4, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced the launch of an equity offering by means of a private placement to certain investors, with
Read more →MDXHMDxHealth Appoints New Scientific Advisory Board
DURHAM, NC, and LIEGE, BELGIUM - March 24th, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has appointed a high profile Scientific Advisory Board (SAB) to support the Compa
Read more →MDXHMDxHealth Reports Full-Year 2010 Results New strategy positively impacts financial and operating results
DURHAM, NC, and LIEGE, BELGIUM - February 21, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced results of operations for the full year 2010. Significantly improved key financial perf
Read more →MDXHMDxHealth Closes Agreement with Pfizer, Newcastle University and CRT to Identify a Predictive Biomarker for PARP inhibitor therapies
DURHAM, NC, and LIEGE, BELGIUM - January 31, 2010 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has signed an agreement with Newcastle University (UK), Cancer Research Technolog
Read more →MDXHMDxHealth Biomarkers Used in Successful Testing of Predictive Biosciences' Bladder Cancer Assay
Data Presented at GTCbio's Oncology Biomarkers Conference DURHAM, NC, and LIEGE, BELGIUM - January 26, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its partner, Predictive B
Read more →MDXHMDxHealth Licensee Exact Sciences Confirms Use of Biomarker and Methylation Technology in its Advanced Colon Cancer Test
DURHAM, NC, and LIEGE, BELGIUM - January 10, 2011 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that Exact Sciences (Nasdaq: EXAS) has confirmed that it is using an MDxHealth methylatio
Read more →MDXHMDxHealth Expands Its Companion Diagnostics Capabilities
DURHAM, NC, and LIEGE, BELGIUM- December 21, 2010 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has expanded its presence and capabilities in the growing field of companion diag
Read more →MDXHMDxHealth Amends Existing Methylation Biomarker Agreement with Veridex, LLC
Partnering of Cancer Screening Applications Supports MDxHealth's New Strategy DURHAM, NC, and LIEGE, BELGIUM - December 15, 2010 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced it has re
Read more →MDXHMDxHealth Licenses Methylation Technology to Takara Bio Inc. for Scientific Research Market
DURHAM, NC, and LIEGE, BELGIUM - November 29, 2010 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has granted a non-exclusive worldwide license for its patented methylation speci
Read more →MDXHMDxHealth Licenses Biomarkers for Bladder Cancer to Predictive Biosciences
DURHAM, NC, LIEGE, BELGIUM and LEXINGTON, MA - November 22nd, 2010 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has agreed to out-license certain DNA methylation biomarkers to
Read more →MDXHMDxHealth Provides Third Quarter 2010 Business Update
DURHAM, NC, and LIEGE, BELGIUM - November 4, 2010 - MDxHealth SA (NYSE Euronext Brussels & Amsterdam: MDXH), a leading molecular diagnostics company focused on personalized medicine in the field of cancer, today issued its business update for the quarter ended September 30, 2010.
Read more →MDXHMDxHealth Outlines New Strategy
Focus on molecular diagnostic testing for personalized medicine in oncology DURHAM, NC, and LIEGE, BELGIUM - October 19, 2010 - MDxHealth (NYSE Euronext: MDXH), a leading molecular diagnostics company, formerly known as OncoMethylome Sciences, today announced further details reg
Read more →Competitive Position
How MDXH ranks across every disease it competes inCompetitive Position is a premium feature
See how MDXH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial